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CHAPTER I 
 
INTRODUCTION 
 
The average human body contains trillions of cells that initially arose from 
one dividing zygotic cell.  The decision to divide is carefully regulated 
throughout a human lifespan by the cell cycle.  Except for cells in specific niches 
in the adult body, cells in adult humans are quiescent and not actively dividing.   
 Improper control of cell division can lead to aberrant proliferation of cells 
and under certain conditions to the formation of a tumor and eventually a 
carcinoma.  Many mutations linked to human cancers disrupt control of the cell 
cycle and cause cells to divide aberrantly (1).  Changes in the cellular genome 
occur in every tumor, and genomic instability is a hallmark of cancer (2, 3).   
Where do these genetic changes come from?  With each cell division, DNA 
must be faithfully replicated.  In human cells there are six billion bases of DNA 
to copy each time the cell divides, and trillions of cell divisions occur in a human 
lifespan. The amount of DNA itself that must be perfectly copied in a lifetime is a 
daunting task, and mistakes can occur.  Cellular processes also produce reactive 
metabolites and oxidation products that damage DNA. Finally, exogenous 
sources of DNA damage like radiation and other genotoxins are prevalent in the 
environment.  This combined assault on DNA yields tens of thousands of DNA 
lesions per day in every human cell.   
In response to DNA damage, an evolutionarily conserved DNA damage 
response (DDR) elicits DNA damage checkpoints to coordinate cell cycle 
progression, DNA repair, DNA replication, DNA transcription, and even 
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programmed cell death to promote genome maintenance.  Genome maintenance 
via the DDR is essential to prevent disease.  Disruption of many DDR genes 
results in lethality, cancer susceptibility syndromes, neurodegenerative 
disorders, and premature aging syndromes (4). 
 
Cell cycle and genome duplication 
 The cell cycle controls cell division and, except for during embryonic 
development, consists of Gap 1 (G1), DNA Synthesis (S), Gap 2 (G2), and Mitotic 
(M) phases.  Modulation of cyclin-dependent kinase (CDK) activity controls cell 
cycle progression.  CDK activity is controlled at several levels including, 
requisite activation by cyclins, regulation of cyclin levels (Figure 1a), inhibition 
by CDK inhibitors (CKIs), and phosphorylation.   The following overview of 
each of the cell cycle phases highlights some of these mechanisms and serves to 
introduce pathways that are also regulated by the DDR.  It is by no means a 
comprehensive overview.   
 
G1 phase 
The decision to divide is determined in the G1 phase of the cell cycle.  
External mitogenic signals and nutrient availability are integrated by the cell, 
and expression levels of cyclin D rise.  Cyclin D binds and activates CDK4/6. 
Inhibitory phosphates are also removed from CDK4/6 by the CDC25 family of 
phosphatases.  Cyclin D-CDK4/6 phosphorylates the tumor suppressor 
retinoblastoma (RB) pocket protein (5, 6).  RB binds and inhibits the E2F family of 
transcription factors (Figure 1b, orange panel). 
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Phosphorylation of RB relieves this inhibition allowing transactivation of E2F 
target genes, which include cyclin E and proteins required for genome 
duplication in S phase (6, 7).   
 
S phase  
Following G1, DNA synthesis occurs in S phase.  DNA replication 
requires formation of a pre-replication complex (pre-RC) in the G1 phase (Figure 
1b, small orange panel).  Pre-RC formation includes binding of origin recognition 
complexes (ORCs) to replication origins, ORC-dependent recruitment of Cdc6 
and Cdt1, and loading of the mini-chromosome maintenance (MCM) helicase 
complex (8-10).  Pre-RCs remain inactive in this state until S phase when cyclin 
E-CDK2 and cyclin A-CDK2 activity is high.  CDK2 and Cdc7/Dbf4-depedent 
kinase (DDK) activities initiate replication origin firing at pre-RCs through 
recruitment of Cdc45 and GINS, which activate the MCM helicase and promote 
DNA unwinding and polymerase recruitment (Figure 1b, blue panel) (11).  DNA 
synthesis occurs in a bi-directional manner.  These replication structures are 
called replication forks, and the replication proteins associated at these forks are 
collectively called the replisome (12, 13).  
Loading of pre-RCs and initiation of DNA synthesis occur in separate 
phases of the cell cycle to ensure DNA is replicated only once.  CDK activity is 
low in G1 when pre-RCs are formed but high throughout the rest of the cell 
cycle. Once an origin has fired in S phase, it will not be re-replicated, since pre-
RCs can only form in G1.  This is because CDK activity inhibits pre-RC formation 
at origins by phosphorylating all components of the pre-RC and negatively 
regulating these proteins through proteolysis and subcellular localization (14).  
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Preventing re-replication of DNA is essential to maintain genome integrity, as 
replicating certain regions more than once would change DNA copy number and 
perturb chromosome segregation (15). 
  
G2 and M phases 
Following DNA synthesis, the G2 phase of the cell cycle serves to prepare 
the cell for segregation of chromosomes in mitosis.  This includes synthesis of 
proteins required for mitosis including cyclin B.  The transition from G2 to 
mitosis occurs when a threshold of activated nuclear cyclin B-CDK1 is reached  
(Figure 1b, pink panel).  In addition to complexing with cyclin B, removal of 
inhibitory phosphorylation on CDK1 by the CDC25 phosphatase is required for 
CDK1 activity (16).  Once cyclin B-CDK1 activity levels are high, mitosis occurs, 
which includes segregation of duplicated chromosomes into to two daughter 
cells.  Exit from mitosis is enacted by degradation of cyclin B (Figure 1b, green 
panel) (16).   
 
DNA damage checkpoints 
 Each phase of the cell cycle is tightly regulated through control of cyclin-
CDK activity to ensure proper progression.  The penultimate goal of this 
complex system is to ensure the genome is duplicated only once and properly 
segregated into two cells (17).  Yet in each phase of the cell cycle, DNA is 
susceptible to damage, and this damage could be replicated and propagated to 
daughter cells.  To prevent this, the DDR enacts checkpoints that inhibit many of 
the cell cycle components in addition to regulating DNA repair and cell death.   
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At the apex of the DDR are three related protein kinases, Ataxia-
telangiectasia Mutated (ATM), ATM and Rad3-related (ATR), and DNA-
dependent protein kinase (DNA-PK).  While DNA double-strand breaks (DSBs) 
activate ATM and DNA-PK, many types of DNA damage activate ATR, 
including DNA replication stress, DNA DSBs, base adducts, and crosslinks (18).  
Once activated, these kinases preferentially phosphorylate serines and 
threonines followed by a glutamine (S/TQ) (19, 20) in hundreds of protein 
substrates to halt cell cycle progression, regulate DNA repair, and elicit cell 
death.  In the next section I will introduce how the DDR enacts cell cycle 
checkpoints to halt progression in the presence of DNA damage. 
 
G1 and G2 checkpoints 
If DNA damage occurs in G1, activation of the DDR prevents progression 
into S phase primary through ATM-mediated stabilization of the tumor 
suppressor protein p53 (Figure 2a) ATM directly phosphorylates p53 and the 
ubiquitin ligase MDM2, which targets p53 for proteolysis.  ATM also 
phosphorylates and activates the effector kinase Chk2, which also 
phosphorylates p53.  ATM and Chk2 phosphorylation of p53 in both cases 
functions to stabilize p53.  p53 transactivates expression of the CKI, p21, which 
binds and inhibits cyclin E-CDK2.  Chk2 also phosphorylates CDC25, targeting 
the CDK-activating phosphatase for degradation (21).  Inhibition of cyclin E- 
CDK2 prevents phosphorylation of RB and initiation of DNA synthesis and 
induces a G1 arrest.  p53 also transactivates programmed cell death genes and 
promotes genome maintenance through culling of cells with DNA damage (22).   
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Aberrant regulation in all of these components is found in many types of cancer 
(23-26). 
A DNA damage checkpoint also occurs in G2 to prevent entry into mitosis 
with damaged DNA.  This checkpoint is mediated by the ATM-Chk2 and ATR-
Chk1 pathways. ATM and ATR activation leads to the phosphorylation of the 
effector kinases Chk2 and Chk1, respectively.  Both Chk2 and Chk1 
phosphorylate the CDC25 phosphatase targeting it for proteasome-mediated 
degradation.  Degradation of CDC25 prevents removal of inactivating 
phosphorylations on cyclin B-CDK1, which is required for entry into mitosis 
(Figure 2b) (23, 27-29).   
  
S phase checkpoint and DNA replication stress 
DNA is particularly vulnerable during the process of DNA replication.  
DNA is normally double-stranded, wrapped around proteins called histones, 
and compacted into higher order structures.  During replication histones are 
removed, and DNA is unwound to a single-stranded state to facilitate semi-
conservative replication.  Furthermore, unwinding DNA creates topological 
problems.  Enzymes nick and break the DNA in order to relieve this topological 
stress.  These processes alone put the genome in a precarious state during DNA 
replication.  The possibility of DNA damage further increases during replication, 
as the replisome can encounter obstacles on the DNA that can prevent replication 
fork progression (30).   
Impeding replication fork progression causes what is collectively termed 
DNA replication stress.  DNA damage, proteins tightly bound to DNA, lack of 
sufficient deoxynucleotides, and even difficult to replicate sequences are all 
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sources of DNA replication stress (31-33).  In response to DNA replication stress, 
the ATR kinase is activated and enacts the intra-S phase checkpoint by 
phosphorylating the effector kinase Chk1 and other substrates to block cell cycle 
progression, regulate origin firing, stabilize stalled replication forks, restart 
collapsed forks, and prevent premature chromatin condensation in the presence 
of incomplete DNA replication (Figure 3) (18, 34, 35).  ATR, unlike ATM and 
DNA-PK, is an essential gene in replicating cells (36-38).  This probably is due to 
ATR activation by replication stress in every S phase and perhaps regulation of 
specific aspects of DNA replication such as origin firing or nucleotide 
production.   
Replication stress often results in the generation of excess ssDNA.  In 
addition, replication stress can lead to collapse of replication forks and 
generation of DNA double-strand breaks (DBSs) (39-42).  Both ssDNA and DNA 
DSBs are highly recombinogenic.  If they are not properly resolved, illicit 
recombination and genome rearrangements can occur.  Disruption of replication 
proteins, such as DNA ligase, DNA polymerases, MCM4, and replication protein 
A (RPA), increases spontaneous chromosomal exchanges (43-47). Disruption of S 
phase checkpoint proteins, including the S. cerevisiae homolog of ATR, Mec1, 
causes an increase in chromosomal rearrangements (48, 49).  In addition anti-
recombinational helicases are regulated by ATR as part of the S phase checkpoint 
to suppress aberrant HR of replication intermediates.  Deletion of these helicases 
results in human diseases and hyper-recombination in cells derived from these 
patients (50-52).   
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  Because ATR is essential, homozyogous loss of function mutations are not 
compatible with life.  Mice with ATR deleted die before embryonic day E7.5.  
Mouse embryonic fibroblasts from ATR null mice undergo cell cycle arrest and 
cell death in the absence of exogenous DNA damage (36-38).  However, 
hypomorphic alleles of ATR that cause reduced protein levels due to a splicing 
error cause a rare disease called Seckel Syndrome.  Seckel Syndrome patients 
exhibit short stature, microcephaly, and mental retardation thought to be 
attributed to proliferation defects during development (53, 54).  In addition, ATR 
is a haploinsufficient tumor suppressor in certain genetic backgrounds.  
Hypomorphic ATR mutations in microsatellite instability tumors are associated 
with reduced overall survival and disease-free survival (55, 56), and mutations of 
ATR substrates are associated with cancer (57, 58).  Thus responding to 
replication stress via the ATR pathway is essential to prevent genetic changes 
and disease.  The functions of ATR in responding to replication stress will be 
discussed in depth later. 
 
DNA replication stress and cancer 
Inactivation of many DNA repair genes in the germline results in 
hereditary cancer predisposition syndromes (59). Disruption of DNA repair 
pathways, especially error-free repair pathways like homologous recombination, 
leads to increased genetic changes that can promote cancer development (Figure 
4a).  This paradigm is often referred to as the “mutator hypothesis.”  The source 
of genomic instability in this case comes from an inherited defect in DNA repair 
(60-63).   
 12 
Chromosomal instability is also a hallmark in sporadic cancers.  However 
in sporadic non-hereditary cancers, the source of genetic changes is 
unclear.  Sequencing studies in sporadic cancers before treatment reveal that 
very few genes, including DNA repair genes, are mutated at high frequency (64-
68).  This suggests that in sporadic cancers early inactivation of DNA repair 
genes is a rare event.  Interestingly, the few genes mutated at frequencies over 
20% included P53, EGFR, RAS, p16, and PTEN (69).  These genes encode for 
classical oncoproteins or negative regulators of oncoprotein activity.   
Because oncogenes are frequently mutated in sporadic cancers, it has been 
hypothesized that oncogene activation leads to genomic instability.  How can 
oncogenes cause DNA damage?  It is now known that oncogene-driven 
proliferation in tumor-derived cell lines and xenograft models causes DNA 
replication stress, activation of the ATR-Chk1 pathway, loss of heterozygosity, 
and genome rearrangements (70-72).  These data have led to the “oncogene-
induced replication stress” hypothesis, which predicts that 1) mutations in genes 
that regulate entry into S phase occur at a high frequency, 2) DNA replication 
stress is present in early non-malignant neoplasias, 3) the DDR is activated and 
prevents tumor development, and 4) bypass of the DDR promotes progression to 
malignancy (73, 74).   
In support of the first prediction, mutations in oncogenes (EGFR, RAS) 
that drive S phase entry and tumor suppresors (PTEN, p16, p53) that function to 
oppose these oncogenes are mutated at high frequency (69). Evidence also 
supports that DNA replication stress is present in early precancerous lesions.  
Common fragile sites are difficult to replicate regions of the genome.   
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DNA replication stress causes DNA breaks and gaps at common fragile sites 
leading to their rearrangement and can be considered a signature for replication 
stress (75).  Two independent studies show that common fragile sites exhibit 
allelic imbalance in precancerous lesions (71-74).  Importantly, allelic imbalance 
is not increased at other chromosome loci that frequently exhibit allelic 
imbalance in advanced cancers (71-74).  
DDR activation occurs in precancerous neoplasias but not in adjacent 
normal tissue in several studies supporting prediction three (71-74).  In support 
of prediction four, p53 protein levels were increased and apoptotic cells were 
observed in premalignant neoplasias.  While DDR activation was still present in 
advanced cancers, apoptosis was suppressed and correlated with p53 mutations 
(71-74).  Thus while p53 deletions in mouse models and human cells does not 
cause aneuploidy, it may be that bypass of the DDR occurs frequently through 
p53 inactivation, accounting for the high frequency of p53 mutations in cancers.  
These data have led to a new paradigm in cancer biology and genome 
maintenance, whereby DNA replication stress induced by oncogene activation is 
a major contributor to genomic instability in tumors (Figure 4b).  Replication 
stress generates ssDNA and DNA DSBs, which activate ATR and the DDR to 
facilitate proper replication, DNA repair, cell cycle arrest, and cell death or 
senescence.  Thus ATR and the DDR are thought to be a barrier to tumor 
development.  Bypass of this barrier via p53 mutations, for instance, may allow 
for selection of cells with genetic changes due to improper repair of ssDNA and 
DNA DSBs.   
However, bypass of the DDR may be a double-edged sword for the cancer 
cell.  There may be an increased dependency on the ATR pathway, analogous to 
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oncogene addiction, to continue to replicate in the presence of oncogene-induced 
replication stress.  Understanding how cells maintain genome integrity during 
replication stress is necessary to gain insights into the pathology of cancer and 
other diseases.  Furthermore, because many cancer cells experience increased 
replication stress, we may be able to develop therapies targeting ATR and the 
replication stress response.   
 
ATR regulation 
It is clear that ATR is essential as one of the major controllers of the DDR 
to replication stress.  I have focused my dissertation studies on understanding 
how ATR is regulated in order to gain insights into how cells maintain their 
genomes.  In the follow section, I will outline major points known about ATR 
regulation. 
 
ATR and RPA-ssDNA 
Replication protein A (RPA) is a single-stranded DNA (ssDNA) binding 
protein that consists of three subunits, RPA32, RPA14, and RPA70.  RPA affinity 
for ssDNA is high, and RPA binding stabilizes ssDNA.  In addition, protein 
interactions with RPA serve to recruit DNA replication, ATR, and other DDR 
proteins to RPA-ssDNA (76).  RPA is normally associated with ssDNA even 
during replication, but it becomes hyperphosphorylated by the DDR (77-79).   
 The most common signal to activate ATR in response to replication stress 
is likely to be RPA-ssDNA (80).  This is because while replication stress blocks  
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replication forks in many ways, RPA-ssDNA can be generated directly or 
indirectly from many types of replication stress.  For example, some types of 
replication stress stall the DNA polymerase but not the replicative helicase (81).  
This functional uncoupling of enzymatic activities allows the helicase to continue 
to unwind DNA while the polymerase remains blocked, generating stretches of 
unreplicated ssDNA that becomes bound by RPA (Figure 5a). Functional 
uncoupling of the replisome occurs in cases of nucleotide depletion, polymerase 
inhibition, UV-generated thymidine dimers, and any type of lesion that blocks 
the polymerase but not the helicase.  Re-priming can occur and only a small gap 
may be left behind (Figure 5b) (33, 82).  While lesions, such as interstrand 
crosslinks, block both the polymerase and helicase, enzymatic remodeling of the 
blocked replication fork by helicases and nucleases also creates ssDNA. 
Similarly, nuclease-mediated resection of DNA double-strand breaks (DSBs) 
produces ssDNA (Figure 5c) (83).  These are just a few ways in which ssDNA is 
generated by replication stress. 
 
ATR-ATRIP complex 
ATR forms an obligate complex with the ATR Interacting Protein (ATRIP) 
(36).  ATRIP directly interacts with the 70N subunit of RPA (Figure 6) and 
facilitates the recruitment of ATR-ATRIP to RPA-ssDNA (Figure 7) (84, 85).  ATR 
activity, though it is unclear why, is required for ATR-ATRIP recruitment to 
RPA-ssDNA (86).  There may also be RPA independent modes of ATR-ATRIP 
recruitment (84, 87-89).  In addition to recruitment, ATRIP is required for ATR 
protein stability (36).  Localization of ATR-ATRIP is not sufficient to activate the 
kinase.  Additional protein factors are required, namely the Rad9-Rad1-Hus1  
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complex and the ATR activator TopBP1.  ATRIP directly interacts with TopBP1, 
and this interaction is necessary for TopBP1 to activate ATR (90).  Finally ATRIP 
post-translational modifications regulate ATR function in the G2 DNA damage 
checkpoint (91, 92). 
 
The Rad9-Rad1-Hus1 DNA damage clamp 
Independently of ATR-ATRIP localization to RPA-ssDNA, the DNA 
damage clamp Rad9-Rad1-Hus1 (9-1-1) is loaded onto RPA-ssDNA (Figure 7).  
While 9-1-1 loading can occur on both 5’ and 3’ DNA ends, loading preferentially 
occurs at 5’ ssDNA-dsDNA junctions in the presence of RPA (93, 94).  This 
preferential loading to the 5’ end is likely mediated by an interaction with the 
RPA70N subunit and Rad9 (95).  RPA subunits bind ssDNA with 5’-3’ polarity, 
placing the RPA70 subunit adjacent to a 5’ ssDNA-dsDNA junction (96-98).  5’ 
ssDNA-dsDNA junctions are present in the lagging strand at Okazaki fragments 
during normal replication.  However, during replication stress, re-priming of the 
leading strand by primase can also generate a 5’ssDNA-dsDNA junction, and 
primase activity is important for checkpoint activity (81, 99, 100).  The loading of 
the 9-1-1 complex requires a specialized DNA damage clamp loader RFC-Rad17 
and ATP hydrolysis (93, 94).  The Rad9 subunit of the 9-1-1 clamp functions to 
recruit the ATR activator TopBP1.  The C-terminal tail of Rad9 is constitutively 
phosphorylated.  Phosphorylated Rad9 is recognized by the phospho-binding 
BRCA1 C-terminal (BRCT) repeats 1 and 2 of TopBP1 (Figure 8a).  This 
interaction serves to concentrate TopBP1 in proximity to ATR-ATRIP (101, 102).  
In yeast, the Rad9 homolog, Ddc1, can activate the ATR homolog Mec1 (103), and 
artificial tethering of Ddc1 to chromatin can activate Mec1 in the absence of DNA  
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damage (104).  However, in mammalian systems, Rad9 is not sufficient to 
activate ATR.  TopBP1 fusions with chromatin proteins alleviate the requirement 
of Rad9 and Rad17 in checkpoint signaling in human cells (101, 105).  Based on 
this, the primary function of the 9-1-1 complex in human cells is likely to recruit 
TopBP1. 
 
TopBP1-mediated activation of ATR 
ATR activity in response to DNA damage and replication stress requires 
TopBP1 (90, 106-109).  Once localized to chromatin, a distinct region of TopBP1 
termed the ATR Activation Domain (AAD) interacts with surfaces on both ATR 
and ATRIP and stimulates ATR kinase activity (Figure 7) (90).  TopBP1 binding 
of ATR-ATRIP increases the affinity of ATR for substrates, though how is 
unknown (110).  Disruption of interaction surfaces on ATR or ATRIP 
individually disrupts activation (90).  Ectopic expression of the AAD in human 
cells is sufficient to activate ATR signaling in the absence of DNA damage (84, 
109, 111).  Additionally, tethering of TopBP1 to chromatin in human cells is also 
sufficient to activate ATR signaling (105).  Thus, the recruitment of TopBP1 to 
chromatin is sufficient for ATR signaling and is an important regulatory step.  
TopBP1-mediated activation of ATR is evolutionarily conserved.  The S. cerevisiae 
homolog of TopBP1, Dpb11, activates S. cerevisiae Mec1ATR, and this activating 
activity is localized to the extreme C-terminal tail of Dpb11 (Figure 8b) (112, 113).   
Recent research has made it clear that recruitment of TopBP1 is complex 
and can occur through multiple mechanisms.  These mechanisms may be context 
specific.  In Xenopus extracts, TopBP1 can localize to chromatin independently of 
Rad9 after replication stress (114).  In response to ionizing radiation (IR), a new  
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protein RHINO interacts with both Rad9 and TopBP1 via distinct domains.  This 
interaction is important for ATR signaling after IR, suggesting RHINO may 
bridge the two proteins on chromatin (115).  Finally, new evidence suggests that 
BRCTs 4 and 5 are required for TopBP1 DNA damage foci in G1 but not for DNA 
replication stress (Figure 8b) (116).  Thus, TopBP1 recruitment can occur through 
multiple mechanisms depending on the DNA damage context. 
In addition to recruitment to chromatin, TopBP1 is regulated at the level 
of phosphorylation. ATM phosphorylation of S1138 of TopBP1 potentiates 
TopBP1-mediated activation of ATR after ionizing radiation (117, 118).  In 
addition, T731 in the AAD of Dpb11TopBP1 is likely phosphorylated by Mec1ATR.  A 
T731A mutation mildly reduces the ability of Dpb11 to activate Mec1 at low salt 
concentrations.  However at physiological salt concentrations, the T731A 
mutation greatly reduces the ability of Dpb11TopBP1 to activate Mec1ATR.  A 
phospho-mimicking mutation T731E partially restores Mec1ATR activation at 
physiological salt concentrations, supporting that T731 phosphorylation 
promotes the ability of Dpb11TopBP1 to activate Mec1ATR (112).   
 TopBP1 is essential for DNA replication as well (119-124).  However, 
mutations in the AAD of TOPBP1 that perturb ATR signaling after replication 
stress do not affect DNA replication (107, 124).  Therefore the functions are 
separable, and for clarity I will not introduce TopBP1 functions in replication.   
 
Chk1 
Proteomic screens reveal that ATR phosphorylates hundreds of substrates 
in response to DNA damage (125-128).  The function of the majority of these 
substrates in the replication stress response remains unknown.  However, the 
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best characterized ATR substrate is the kinase Chk1.  Similar to ATR, CHK1 
deletion results in embryonic lethality and replication stress response defects 
(129, 130).  ATR phosphorylates Chk1 on serines 317 and 345 (34, 130).  Chk1 
phosphorylation increases its kinase activity and the kinase undergoes 
subsequent autophosphorylation (131, 132).   
In contrast to other ATR substrates, ATR-dependent Chk1 
phosphorylation has unique protein requirements.  Claspin functions as an 
adaptor protein for Chk1 but not other ATR substrates (108, 133).  There may be 
multiple cooperating mechanisms to localize Claspin to stalled replication forks.  
Claspin associates with the replisome via an interaction with the replication 
protein Cdc45 and may monitor replication as the fork progresses (134).  Claspin 
also interacts with Timeless of the Tipin-Timeless complex, and this interaction 
mediates Chk1 signaling in the S phase checkpoint.  Tipin contains an RPA 
binding motif, which localizes Claspin at RPA-ssDNA (135-138).   
 
ATR-Chk1 and S phase checkpoint 
The function of the ATR-Chk1 axis has been intensely studied in many 
systems.  However studies in the budding yeast S. cerevisiae are the most 
extensive and have provided the foundation of much of what we understand 
about ATR and Chk1.  In budding yeast Mec1ATR and Rad53Chk1 regulate fork 
stability and late origin firing (139, 140).  Replication forks irreversibly collapse in 
MEC1 and RAD53 deleted strains cultured in replication stress agents.  Analysis 
of replication forks in Rad53 mutants after replication stress showed structures 
indicative of collapsed replication forks (141, 142).  Additionally in RAD53 null 
strains the failure to stabilize replication forks during replication stress is 
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irreversible.  This was shown in studies where wild type Rad53 was inducibly 
expressed after release from replication stress in RAD53 null cells.  The re-
expression of Rad53 could not rescue DNA replication after removal of 
replication stress (142).   
In S. cerevisiae replication fork stability and origin firing functions of 
Mec1ATR are genetically separable.  A mec1-100 allele is viable and does not 
exhibit sensitivity to replication stress agents.  The mec1-100 protein cannot 
suppress late origin firing but can stabilize replication forks in the presence of 
replication stress (143).  Thus at least in yeast, suppressing late origin firing is 
dispensable while replication fork stabilization is essential.  Whether this is also 
true in mammalian cells is not known.  Many studies indicate that suppression of 
late origin firing is an important function of ATR-Chk1 in mammalian systems 
(144-147). 
The targets of Mec1 and Rad53 that preserve replication fork stability are 
not well understood, differ in experimental systems, and are not necessarily 
overlapping.  For instance, polymerase chromatin association in yeast during 
replication stress is dependent on S phase checkpoint activity (40, 148, 149).  
However in Xenopus, polymerase reloading can occur in an ATR/ATM 
dependent manner (150).  Also the MCM helicase is phosphorylated by ATR 
(151, 152), and it is hypothesized that this slows unwinding of the DNA.  In 
addition, ATR and Chk1 stabilize replication forks by preventing unwanted 
remodeling of replication forks by nucleases and recombinases. ATR 
phosphorylates anti-recombinogenic helicases such as WRN and BLM (153, 154).  
Mutation of BLM and WRN causes hyper-recombination supporting that 
preservation of fork stability is important to prevent aberrant recombination of 
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fork structures (52, 155).  ATR and Chk1 also target nucleases such as Mus81 and 
Exo1 (156).  Irreversible fork collapse in RAD53 null cells is rescued by EXO1 
deletion (143), suggesting that in the absence of checkpoint signaling nucleases 
aberrantly process replication forks and convert them to a collapsed double-
strand break state.  This is further supported by evidence that markers of 
homologous recombination do not form in the presence of replication stress 
agents in wild type yeast but only when the checkpoint is defective (157).   
Of note, MEC1 deficiency causes cells to be more sensitive to replication 
stress than RAD53 deletion (141, 158).  This suggests that not all ATR functions 
are through Chk1 signaling.  For instance while EXO1 deletion can rescue RAD53 
deletion, it cannot rescue MEC1 deletion(143).  Other cases of Chk1-independent 
functions of ATR in responding to replication stress have been reported in other 
systems as well (159).   
 
Common mechanisms of PIKK regulation 
ATR belongs to the phosphoinositide 3-kinase (PI3K)-like kinase (PIKK) 
family of protein kinases, which includes ATR, ATM, DNA-PK, mTOR, and 
SMG1.  ATR and ATM mediate the DDR, and DNA-PK also functions to 
preserve genome maintenance through its control of DSB repair.  mTOR 
regulates cell growth through nutrient sensing, and SMG1 functions in mRNA 
surveillance.  While their functions are diverse, common themes in PIKK 
regulation have emerged from research.  New modes of ATR regulation may be 
garnered by exploring these shared mechanisms. 
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The PIKKs share domain architecture with a conserved catalytic domain.  
The catalytic domain has sequence homology with the PI3K kinase domain.  
While PI3K is a lipid kinase, the PIKKs are serine/threonine protein kinases.  
Surrounding the C-terminal kinase domains are two regions flanking the kinase 
domain, the FAT and FATC, that exhibit sequence homology among family 
members (110, 160) (Figure 9).  Studies show that the FATC domain is required 
for kinase activity of all the PIKKs (161).  Additionally, modifications and protein 
interactions in the FAT domain modulate kinase activity (162-164).  N-terminal to 
the kinase domain, the PIKKs consist of long arrays of anti-parallel helices called 
HEAT repeats.  HEAT repeats are similar but distinct to ARM-repeats (165).  The 
function of HEAT repeats in classical HEAT repeat proteins is to bind proteins.  
However, Rubison et al demonstrate that HEAT repeats also can mediate 
interactions with DNA (166). 
In addition to domain architecture, the PIKKs also share several modes of 
regulation.  ATR, ATM, DNA-PK, and mTOR are regulated by changes in 
subcellular localization.  Subcellular localization is mediated by protein binding 
partners (Figure 10a).  mTORC1, one of the distinct mTOR complexes, interacts 
with Raptor.  mTORC1 localizes to distinct lysosomal membranes via an 
interaction between Raptor and Rag GTPases found in lysosomal membranes 
(167, 168).  ATR, ATM, and DNA-PK interact with ATRIP, the Mre11-Rad50-
Nbs1 (MRN) complex, and Ku70/80 respectively.  These binding partners 
interact with specific nucleic acid structures and localize the kinases to sites of 
DNA damage (Figure 10a and b) (84, 87, 169).   
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Localization to distinct structures likely functions to concentrate the 
kinases with other regulatory inputs, such as protein activators.  TopBP1 
activates the ATR-ATRIP complex (90, 109).  Similarly, ATM is activated by 
DNA-bound MRN complexes (170, 171), and the Ku70/Ku80 heterodimer bound 
to DNA ends activates DNA-PK (172, 173).  The Rheb GTPase also stimulates 
mTORC1 activity (174).  Kinase activation is mediated by the PIKK Regulatory 
Domain (PRD), which occurs between the kinase domain and the FATC domain 
(Figure 9).  PRD sequences in PIKKs are divergent, suggesting that these 
variations allow the kinases to respond to different regulatory inputs or protein 
activators.  While the sequences are different, the function of the PRD to mediate 
kinase activation seems to be conserved.  In ATR, the PRD serves as a binding 
surface for the ATR activator TopBP1 (90).  Likewise, mutations in the DNA-PK 
PRD disrupt kinase activation following DNA damage (90).  In addition to 
protein binding, the PRD also is post-translationally modified.  ATM acetylation 
in the PRD is required for kinase activation in response to DSB breaks (175, 176).  
mTOR phosphorylation and autophosphorylation also has been mapped to the 
PRD domain (177-179).  The mechanism of how the PRD mediates kinase activity 
is unknown. 
 
Phospho-regulation of ATR 
Phosphorylation also regulates PIKK kinase activity.  ATM, DNA-PK, and 
mTOR undergo phosphorylation (Figure 10).  These phosphorylation events are 
critical regulatory events, as ablation of the phosphorylation sites results in 
cellular defects.  ATM is phosphorylated on several residues, including four 
autophosphorylation sites S367, S1893, S1981, and S2996 (162, 180, 181).  Over 30 
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DNA-PK phospho-residues have been identified and many are 
autophosphorylation sites (182).  Ablation of both ATM and DNA-PK 
autophosphorylation sites causes DNA damage sensitivity (180, 181, 183, 184).  
Furthermore, both ATM and DNA-PK autophosphorylation require their protein 
activators and are direct markers of activated kinases (170, 171, 173).   
The mechanism of how these phosphorylation sites regulate kinase 
activity is not well understood.  The function of ATM S1981 autophosphorylation 
remains controversial.  The initial report of S1981 autophosphorylation purports 
that S1981 phosphorylation mediates transition of inactive ATM dimers to active 
monomers (162).  However, later studies show that S1981 is not required for 
transition to a monomer state (171) and that the murine equivalent of S1981 is not 
required for murine ATM activity (185).   
Two clusters of DNA-PK autophosphorylation have been extensively 
studied and mutation of either of these clusters results in DNA damage 
sensitivity and defective DNA repair.  Mechanistically these phosphorylation 
sites have been linked to modulating DNA association of the kinase, suggesting 
autophosphorylation causes a conformational change in the kinase (186-188).  
Low resolution structures support that there is a shift in protein conformation 
upon kinase activation (189, 190).   
ATR also autophosphorylates in vitro and is a phospho-protein in vivo (36).  
However, the identity of these sites and whether they are DNA damage-
regulated and functional remains unknown.  In my dissertation research I 
explore the possibility that phosphorylation is also an ATR regulatory 
mechanism.  I hypothesize that like ATM and DNA-PK, ATR is phosphorylated 
in response to DNA damage and that this phosphorylation would be a marker 
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for an activated kinase.  I also explore a novel ATR inhibitor and its efficacy as an 
anti-tumor agent.   
 In Chapter III, I identify and characterize T1989 as the first DNA damage-
regulated ATR phosphorylation site.  T1989 phosphorylation occurs concurrently 
with ATR-dependent Chk1 phosphorylation and depends on ATR kinase activity 
in cells.  Mutation of the ATR PRD, which is required for TopBP1-mediated 
activation of ATR, disrupts T1989 phosphorylation suggesting ATR 
phosphorylation occurs downstream of TopBP1 activation of ATR (191).  This 
supports that T1989 phosphorylation occurs on an activated ATR kinase and can 
be used to directly monitor ATR activity in cells.  Although I observed a mild 
viability defect with T1989 mutation, the function of T1989 phosphorylation 
remains unclear.   
I continue exploring potential ATR autophosphorylation sites in Chapter 
IV by mutating and characterizing 16 conserved candidate ATR 
autophosphorylation sites.  A 3A-ATR mutant dissociates essential functions of 
ATR from its G2 checkpoint activities.  Disruption of essential functions of ATR 
correlates with replication stress response defects, suggesting that the essential 
function of ATR in mammalian cells is to respond to replication stress.  This is 
the first separation of function mutant in human ATR reported.  In addition, 
these mutations occur in a distinct region of ATR that is analogous to regions in 
ATM and DNA-PK that are targeted for autophosphorylation.  However, 
whether ATR is phosphorylated at these residues remains unknown.   
My analysis of the 16A-ATR mutations in Chapter IV uncovered a 
potential regulatory region in ATR and an unexpected hyper-stimulation 
phenotype.  In Chapter V, I explore whether conserved residues in this potential 
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regulatory region are also functional in yeast.  I also identify the sites within the 
16 mutations that contribute to the hyper-stimulation phenotype and find they 
are distinct from the 3A-ATR residues.  Preliminary experiments also suggest 
that the hyper-stimulation of ATR by TopBP1 may be due to increased TopBP1 
AAD binding.  
In Chapter VI, I characterize and explore the use of a novel ATR inhibitor 
for basic and translational studies.  Transient inhibition of ATR supports that 
ATR kinase activity is important to stabilize replication forks and to promote 
replication fork restart after replication stress.  Replication stress agents, as well 
as ATM-deficiency, sensitized cancer cells to ATR.   
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CHAPTER II 
 
MATERIAL AND METHODS 
 
DNA constructs and siRNA  
Flag-HA3-WT-ATR was subcloned into the BamHI site of a modified 
pCDNA5/TO vector (Invitrogen).  The BamHI-XhoI fragment (9668-9724) of the 
multiple cloning site was deleted, making the NotI and BstXI sites of the ATR 
cDNA unique.  Two fragments of the ATR cDNA, NotI-BstXI (1-3385) and BstXI-
AgeI (3374-6689), were subcloned into pBSKII(-) with a multiple cloning site 
modified to contain a BstXI site matching the BstXI site found in ATR (pEN3).   
ATR mutants were generated using the QuikChange Site-Directed Mutagenesis 
(Agilent Technologies) method using the primers in Table 1.   Mutated fragments 
were subcloned back into the full length cDNA and verified by sequencing.  In 
some cases the Flag-HA3 epitope was replaced with a single Flag epitope 
(destroys BamHI site) to facilitate purification of HA-ATRIP/Flag-ATR 
complexes by HA-immunoprecipitation.  siGENOME SMARTpool TopBP1 
siRNAs were purchased from Dharmacon.  Plasmid and reverse siRNA 
transfections were carried out with Lipofectamine2000 using the manufacturer’s 
protocol (Invitrogen).   
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Table 1.  Primers used for ATR mutagenesis.  + indicates the restriction site is 
created by mutagenesis.  – indicates that restriction site is destroyed by 
mutagenesis.  Unless noted, primers prime wild-type ATR or do not overlap 
with other mutated residues.   
 
Site Primer name 
Primer sequence 
 Notes 
S749A S749A F 5'-gtaggaacttgaaagccactgctcaacatgaatgttcatct No sites 
S756A S756A F2 5'-cacttctcaacatgaatgttcatcagcgcaactaaaagcttctgtc tgcaag + HhaI  
S756A S756A F3 5'-cactgctcaacatgaatgttcatcagcgcaactaaaagcttctgt ctgcaag 
pEN19 
tem-
plate 
+HhaI 
S927A S927A F 5'-aaaagtgttaaactgcaaagttttttcgcgcagtataagaaaccca tctgtcagttt 
+HhaI; 
+BstUI  
S1333A S1333A F 5'-tgaaacagtagaacctattatcgcacaattggtgacag tgcttttgaaag +MfeI 
S1348A S1333A F 5'-ttgaaaggttgccaagatgcgaatgctcaagctcggttgctctgt +BsmI 
T1376A T1376A F 5'-gtcgattagatttctcaacaactgaagcgcaaggaaaa gattttacatttgtgac 
-SmlI; 
+HhaI; 
+BstUI 
S1464A S1465A F 5'-ctaaataccagatacaagagtgcacagaagtcaaccgattggtct +ApaLI 
T1566A T1566A F 5'-catgacgatcagcataccataaatgcccaagacattgc No sites 
T1566E T1566E F 5'-taaagcatgacgatcagcataccataaatgaacaaga cattgcatctgatctgtg No sites 
T1578A T1578A F 5'-atctgtgtcaactcagtgcacagactgtgttctcc +ApaLI 
T1578D T1578D F 5'-atctgatctgtgtcaactcagtgatcagacagtgttctcc atgcttgaccatc +BclI 
T1589A T1589A F 5'-catgcttgaccatctcgcccagtgggcaaggcaca +BglI 
T1589E T1589E F 5'-ttctccatgcttgaccatctcgagcagtgggcaaggcacaaattt +SmlI; +XhoI 
T1754A T1754A F 5'-agctgtctactgttatcgctcaagtgaatggagtgcatgc +SmlI 
S1782A S1782A F 5'-aagcagcttggaaattggcacagtgggatttggtg No sites 
S1876A S1876A F 5'-cattctccaggtgacagtgctcaggaagattctctaaactgg -SmlI 
T1890A T1890A F 5'-gtagctcgactagaaatggcccaaaattcctacagagccaag -EcoRI 
S2143A S2143A F 5'-ctccatatcaatttttgactgcttttgcacagttgatctctcgaatttgtcatt -MfeI 
T1989A T1989A F 5'-ggtgttgaattatgttttcctgaaaatgaggcgccacctgagggtaag +HhaI 
T1989E T1989E F 5'-gttcttcaaaaaggtgttgaattatgttttcctgaaaat gaagagcctccggagggtaagaacatgttaatcc +BspEI 
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Genetic complementation of ATRflox/-TR cell lines 
Parental HCT116 ATRflox/-TR cells contain one ATR allele disrupted by a 
neomycin cassette, a conditional ATR allele flanked by loxP sites, and an 
integrated cDNA expressing the tetracycline repressor, which confers blasticin 
resistance (90).  To generate clonal ATRflox/-TR stable cell lines expressing 
tetracycline-inducible Flag-HA3-epitope tagged ATR, ATR cDNAs with a 
tetracycline responsive promoter conferring hygromycin B resistance were 
linearized with FspI.  Linearized cDNAs were separated on a 0.8% agarose gel, 
excised, and purified with the QIAquick Gel Extraction Kit.  Extracted DNA was 
further purified by ethanol precipitation.  8  µg of linearized plasmid was 
transfected into 5x106 ATRflox/-TR cells in a 60 mm dish according to the 
Lipofectamine2000 reverse transfection protocol.  24 hours after transfection, cells 
were trypsinized, plated into 100 mm dishes at different dilutions (ie.  1:20, 1:40), 
and selected for stable integrants by maintaining cells in and 10 µg/mL blasticin 
and 300 µg/mL hygromycin B.  Selection media was replaced every 3 days until 
colonies were visible by eye, usually 2-3 weeks.   
To expand single colonies, media was aspirated from dishes, and 5 mL of 
PBS was added to plates.  Using a P200 set for 100 µL, single colonies were 
pipetted off the plate into the tip and transferred to a 12 well dish containing 100 
µL of trypsin.   Cells were pipetted several times in the trypsin.   After several 
minutes, 1 mL of selection media was added and cells were allowed to expand.  
Media was replaced every 2-3 days.   Once wells reached 70-80% confluency, 
integrants were screened for expression of exogenous ATR (see below). 
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Verification of exogenous ATR expression in integrants 
An in-cell western was used initially to screen stable integrants for 
exogenous expression of Flag-HA3-epitope tagged ATR.  500 µL of trypsin was 
added to each 80% confluent 12 well, and then 1 mL of media was added to 
inactivate trypsin.   100 µL of cells were transferred to a 96 well plate containing 
50 µL of media containing tetracycline (final concentration of 1 µg/mL) to induce 
expression of integrated ATR cDNAs.   The remaining 1400 µL of cells were 
transferred to a 6 well plate containing selection media and allowed to expand.    
After 24 hours of growth in tetracycline, medium was aspirated from 96 
well plates and cells were washed once with 100 µL of PBS.   150 µL of 3.7% 
formaldehyde/PBS was to each well for 20 minutes at room temperature.   After 
fixation, cells were washed 5 times with 200 µL of 0.1% Triton-X 100/PBS for 5 
minutes each.   The washes were removed manually with a pipet to prevent 
excessive drying out by aspiration.   150 µL of Odyssey Blocking Buffer was 
added to each well and cells were blocked at room temperature for 1.5 hours.   50 
µL of primary antibodies in Odyssey Blocking Buffer was added to each well 
(HA 1:100 and GAPDH 1:500) for 2 hours at room temperature or overnight at 
4oC.   Cells were washed 5 times with 200 µL 0.1% Tween-20/PBS for 5 minutes 
each time.   50 µL of secondary antibodies in Odyssey Blocking Buffer (anti-
mouse 680 1:500 and anti-goat 800 1:500) was added for 1 hour at room 
temperature.   Cells were again washed 5 times with 0.1% Tween-20/PBS for 5 
minutes each time.   After the final wash, the 96-well plate was inverted and 
firmly tapped onto a kimwipe to remove residual liquid.   Plates were scanned 
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on a Licor Odyssey System using the microplate setting with a 3.0 mm focus 
offset.    
Integrants with in-cell western HA-ATR signals similar to the WT-ATRflox/-
TR cell line were carried forward for western blot analysis and 
immunofluorescence.  Western blotting was used to verify that integrants 
expressed full length ATR to similar levels in the WT-ATRflox/-TR cell line.   
Immunofluorescence was also conducted on integrants for HA expression and 
compared to the WT-ATRflox/-TR cell for similar percentages of cells expressing 
integrated cDNAs.   Two stable integrants expressing similar levels of full length 
Flag-HA3-ATR in a similar percentage of cells were analyzed when possible to 
account for potential clonal differences.    
 
Adenovirus infection 
 To delete the ATRflox allele, 1x106 cells were plated in a 100 mm tissue 
culture dish the day before infection in media containing 1 µg/mL tetracycline.   
The next day, 0.42 µL of adenovirus encoding for Cre-recombinase (AdCre) or 
GFP (AdGFP) was added to cells in 10 mL of media contain tetracycline.   24 
hours after adenovirus addition, adenovirus media was replaced with media 
containing tetracycline.   Functional analysis was conducted 72-96 hours post-
infection. 
 
PCR genotyping, RT-PCR, and sequencing of products 
Genomic DNA was harvested from cells using the Qiagen DNeasy Blood 
and Tissue Kit.   300 ng of genomic DNA was used in PCR reactions containing 
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Taq DNA polymerase (Invitrogen), 1.5 mM MgCl2, 200 µM dNTPs, and 200 nM 
primers.   Primers used were:  ATR8961:  5’-GTCTACCACTGGCATAACAGC 
and sfiloxpseq: 5’-CAGCGGGAGCAGGCATTTCC.   Cycling parameters used 
were:  95oC 2’; [95oC 45”, 58oC 45”, 72oC 70”]x33; 72oC 5’.   Products were run on a 
0.8% ethidium bromide agarose gel and visualized on a BioRad gel 
documentation system.   
 RNA was extracted from ATRflox/-TR, WT-ATRdel/-TR and T1989A-ATRdel/-
TR cell lines using the Qiagen RNeasy Kit.   RT-PCR reactions contained 1 µg of 
RNA, either 5 µM oligo(dT)23 or 7.5µM hexamer primers (USB First-Strand cDNA 
Synthesis Kit), 500 µM dNTPs, 10 units RNase inhibitor, and 1µL M-MLV RT in a 
20 µL reaction volume.   Cycling parameters were:  44oC 60’; 92oC 10’; 4oC as 
needed.   To amplify across the coding region of ATR T1989, RT-PCR and 
genomic DNA products were amplified using the following primer pairs:   
 
1. ATR5877:  5’-GGCAAAGTGGCTCTGGTCCAAG 
ATR6041rev:  5’-GCTGTTTCTTCCATAAATCGGCCC 
 
2. ATR5902:  5’-GATGTTCACCAGGCACTAATTGTTC 
ATR6099rev:  5’-TGGCAGGCACGCGGTCACATC 
 
3. ATR5902:  5’-GATGTTCACCAGGCACTAATTGTTC 
ATR6041rev:  5’-GCTGTTTCTTCCATAAATCGGCCC. 
 
 40 
PCR products are: primer pair 1 – 165 base pairs, primer pair 2 – 198 base pairs, 
and primer pair 3 – 140 base pairs.   Mutation of ATR T1989 to alanine creates an 
HhaI restriction site within the PCR products.   In addition to cleavage by HhaI, 
amplified RT-PCR and genomic DNA products were sequenced using either 
ATR5877 or ATR5902 to verify that T1989A-ATRdel/-TR cell lines express only the 
integrated mutant cDNA.    
 
Western blots and immunoprecipitations 
Drugs were added to cells at the following concentrations: 2mM HU, 
50J/m2 UV, 5Gy IR, 10mM caffeine, 10 M ATM inhibitor (KU55933) (192), 1µM 
DNA-PK inhibitor (NU7441) (193), 50µM Roscovitine, 100nM Chk1 inhibitor 
(AZD7762) (194),  and  3µM ATR inhibitor (AZ20).  Cell lysates were prepared by 
resuspending pellets in NP-40 buffer (1% NP-40, 200mM NaCl, 50mM Tris pH 
8.0), incubating on ice for 20 minutes, and centrifuging at 16xg for 20 minutes at 
4oC.   Protein quantification was done using a BSA standards and the BioRad 
Bradford reagent system.  Immunoprecipitations were performed overnight at 
4oC using 5 µg of antibody and protein G agarose (Santa Cruz), washed three 
times with NP-40 buffer, and separated by SDS-PAGE prior to immunoblotting.  
For lambda phosphatase experiments, ATR immunoprecipitates were washed 
three times with NP-40 buffer and then incubated with lambda phosphatase 
(NEB) for 30 minutes at 37oC.   
For dot blots, peptides were dissolved in 50% acetonitrile, serial diluted in 
water, and spotted directly onto nitrocellulose membranes.   Antibodies used 
included: ATR-N19 (Santa Cruz), Chk1-G4 (Santa Cruz), phosphorylated-S317 
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Chk1 (Cell Signaling), phosphorylated-S345 Chk1 (Cell Signaling), 
phosphorylated-S296 Chk1 (Cell Signaling), HA (Covance), Flag-M2 (Sigma), 
ATRIP-403 (36), and phosphorylated-S428 ATR (Cell Signaling).  The 
phosphorylated-ATR antibody was generated by Bethyl Laboratories using a 13 
amino acid human ATR peptide antigen with phosphorylated T1589 at position 
7.  A cysteine was added to the N-terminus to facilitate conjugation to a carrier.  
All immunoblotting was performed with infrared-conjugated secondary 
antibodies (LiCor) and quantified using an Odyssey system.   
 
Immunofluorescence 
 Cells were seeded on glass coverslips in 6 well plates in media containing 
tetracycline to induce expression of integrated ATR cDNAs.   24 hours later, cells 
were treated with 2mM HU for 6 hours to examine ATR recruitment to stalled 
replication forks.   Prior to fixation, the soluble fraction was extracted with 1mL 
of Triton X-100 solution (0.5% Triton-X 100, 20mM HEPES pH 7.4, 50mM NaCl, 
3mM MgCl2, 300mM sucrose) for 10 minutes on ice.   Cells were carefully 
washed 3 times with 1mL of PBS and fixed with 2mL of 3% paraformaldehyde 
for 10 minutes at room temperature.   2mL of cold Triton-X 100 solution was 
added for 5 minutes on ice and then washed 5 times with PBS.   Cells were 
blocked in 5% BSA/PBS for 15 minutes at room temperature.   Coverslips were 
incubated cell side down onto 40µL of primary antibodies diluted in 5% 
BSA/PBS for 1 hour at 37oC on parafilm.   After primary incubation cells were 
washed 2 times with 2mL of PBS and then incubated with 40µL of secondary 
antibodies for 30 minutes at 37oC cell side down on parafilm.   Cells were washed 
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3 times with PBS and then mounted with Prolong Gold antifade mounting 
reagent containing DAPI.   Antibodies and dilutions used were:  HA 1:100 
(Covance), Flag-M2 1:100 (Sigma), ATRIP-403 1:1000 (36), anti-mouse FITC 1:100 
(Jackson Laboratories), and anti-rabbit rhodamine red 1:300 (Jackson 
Laboratories).    
 
Colony formation and cell viability 
For colony formation assays, 1x103, 5x103, and 1x104 cells were plated in 
triplicate in 60 mm dishes containing media and tetracycline after AdCre or 
AdGFP infection.   Colonies were allowed to form over 2 weeks and then were 
stained with methylene blue.   Colonies were manually counted and percent 
viability is reported as a ratio of AdCre/AdGFP to correct for plating efficiency 
differences among cell lines.     
 For AZ20 experiments, cell viability was assessed by subG0/G1 DNA 
content by propidium idodide staining.   Viability was also determined using the 
Alamar blue reagent.   2000 cells were plated in 96 wells in triplicate.  24 hours 
later, AZ20 was added at 0.001, 0.01, 0.0333, 0.1, 0.333, 1.0, 3.333, and 10 µM.  
 
G2 checkpoint 
For G2 checkpoint assays, cells were irradiated with 8 Gy ionizing 
radiation and 30 minutes after irradiation were transferred to media containing 
nocodazole.   8 hours after release into nocodazole both the media and cells were 
harvested and fixed in 70% ice cold ethanol at -20oC for at least 1 hour.   To 
quantify the mitotic index, ethanol fixed cells were pelleted at 1.8xg for 5 
minutes.   Pellets were resuspended in 1mL of cold PBS and incubated on ice for 
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10 minutes.   Cells were pelleted and resuspended in 1mL of ice cold 0.25% 
Triton-X 100/PBS and incubated on ice for 15 minutes to permeabilize.   Cells 
were pelleted and rinsed once in 1% BSA/PBS and were incubated for 1.5 hours 
at room temperature with 100µL of phospho-S10 Histone H3 (Bethyl) diluted 
1:2000 in 1% BSA/PBS.   Cells were washed 2 times without resuspending with 
1mL of 1% BSA/PBS and then incubated with 100µL of anti-rabbit FITC 
secondary (Jackson Laboratories) diluted 1:75 in 1% BSA/PBS for 1 hour at room 
temperature.   Cells were washed once in 1% BSA/PBS and once in PBS without 
resuspension.   To stain DNA, cells were incubated with 1mL of PBS containing 
25µg/mL propidium iodide and 0.1mg/mL RNase A for 30 minutes at 37oC.   
Samples were filtered and analyzed by flow cytometry.   Mitotic cells were 
determined to be FITC positive cells with 4N DNA content.    
 
Completion of DNA synthesis after replication stress 
For analysis of completion of DNA synthesis after exposure to replication 
stress, cells were arrested with 2mM HU for 24 hours.   HU was removed and 
cells were washed 2 times with equilibrated media.   Cells were released into 
media containing 100ng/mL nocodazole and media and cells were harvested at 
indicated time points.   Cells were fixed in 70% ethanol at -20oC for at least 1 
hour.   To analyze DNA content, cells were pelleted and resuspended into 1mL 
of PBS containing 25µg/mL propidium iodide and 0.1mg/mL RNase A for 30 
minutes at 37oC.   DNA content by propidium iodide was then determined by 
flow cytometry.    
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BrdU incorporation 
For BrdU incorporation experiments, cells were incubated with 
equilibrated media containing 10µM BrdU for 15 minutes and collected.   Cells 
were fixed by adding 70% ice cold ethanol dropwise while vortexing and then 
incubating cells at -20oC for at least 1 hour.   Cells were pelleted at 1.8xg for 5 
minutes and washed once in 0.5% BSA/PBS.   Cells were permeabilized and 
DNA was denatured by adding 1mL of 2N HCl/0.5% Triton-X 100/PBS 
dropwise while vortexing and incubating for 30 minutes at room temperature.   
Cells were pelleted and incubated in 1mL of 0.1M sodium borate for 2 minutes.   
Cells were washed once with 1mL of 0.5%BSA/PBS and then incubated with 
100µL of BrdU-Alexafluor488 antibody diluted 1:20 in 0.5% BSA/PBS/0.5% 
Tween-20 for 30 minutes at room temperature in the dark.   Antibody was 
removed and 1mL of 0.5% BSA/PBS was added to wash one time.   1mL of PBS 
containing 5µg/mL propidium iodide and 0.1mg/mL RNase A was added and 
incubated for 30 minutes at 37oC.   Samples were then analyzed by flow 
cytometry.    
 
Mass spectrometry and sequence alignments 
Endogenous ATR-ATRIP complexes immunoprecipitated from HU 
treated HeLa cells with an anti-ATRIP antibody was excised from an SDS-PAGE 
gel, reduced and alkylated with DTT and iodoacetamide, and subjected to in-gel 
digestion using a variety of proteases including trypsin, chymotrypsin, endo-
AspN and elastase using standard procedures.   Peptides were extracted with 
60% acetonitrile, 0.1% formic acid, dried by vacuum centrifugation, and 
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resuspended in 0.1% formic acid for analysis by liquid chromatography coupled 
with tandem mass spectrometry using an LTQ linear ion trap mass spectrometer 
(ThermoScientific) operated using standard data-dependent (top-five) 
acquisition including neutral loss ms3 acquisition.  Spectra were searched against 
the human uniprot_kb databse (v155, July 2009) concatenated with the reverse 
database using the Sequest algorithm allowing for +80 mass shifts on serine, 
threonine and tyrosine residues.    
For T1989 conservation, full length protein sequences were aligned with 
ClustalW2 (195).   Conservation of S/TQ residues was determined by sequence 
alignment of ATR orthologs using ClustalW2.   Secondary structure alignments 
by HEAT repeats is described in (165).   DNA-PK secondary structure 
predictions were determined by Jpred3 (196). 
 
ATR kinase reactions  
 All ATR kinase reactions were carried out on beads.   For TopBP1-
mediated activation of ATR in vitro, ATR-ATRIP complexes were HA-
immunopurified from nuclear extracts prepared from 293T cells transiently 
expressing Flag-ATR and HA-ATRIP.   HA-immunoprecipitations were carried 
out at 4oC for no more than 3 hours and were washed 3 times with 1mL of TGN 
lysis buffer (50mM Tris pH 7.5, 150mM NaCl, 10% glycerol, and 1% Tween-20), 1 
time with TGN lysis buffer containing 500mM LiCl, and 2 times with kinase 
buffer (10mM HEPES pH 7.5, 50mM NaCl, 10mM MgCl2, 1mM DTT, 50mM Beta-
glycerophosphate).   To the purified kinases 10pmol of recombinant GST or GST-
TopBP1-AAD (ATR Activation Domain) was added and then 30µL of kinase 
buffer containing 0.5µg of recombinant GST-MCM2 substrate, 10µM cold ATP, 
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and 1µL of  γ32P-ATP (Perkin Elmer) was added to the complexes.   Reactions 
were incubated at 30oC for 20 minutes, and reactions were stopped by addition of 
30µL of 2X LSB and boiling for 5 minutes.   For phospho-peptide maps of GST-
AAD stimulated ATR-ATRIP complexes, reactions were carried out in the 
absence of GST-MCM2 substrate and for 30 minutes at 30oC.    
 For ATR autophosphorylation kinase reactions, Flag-ATR was 
immunopurified from 293T cells transiently expressing Flag-ATR and HA-
ATRIP.   Flag immunoprecipitations were carried out in TGN lysis buffer 
overnight at 4oC.   Immunoprecipitations were washed 3 times with TGN lysis 
buffer, 1 time with TGN lysis buffer containing 500mM LiCl, and 2 times with 
kinase buffer.   Kinase complexes were incubated with 30µL of kinase buffer 
containing 10µM cold ATP and 1µL of γ32P-ATP for 30 minutes at 30oC.   
Reactions were stopped with addition of 30µL of 2X LSB and boiled for 5 
minutes.  All reactions were separated by SDS-PAGE and protein levels were 
determined by Coomassie blue staining or by western blot.   32P incorporation 
was analyzed by phosphorimaging or by autoradiography.    
 
Phospho-peptide analysis 
For in vitro phospho-peptide analysis, ATR-ATRIP complexes were 
immunopurified, subjected to kinase reactions, and prepared for phospho-
peptide mapping.   GST-AAD stimulated complexes were phosphorylated for 30 
minutes.   For in vivo phospho-peptide analysis, two 10 cm plates of 293T cells 
overexpressing Flag-HA3-ATR and myc-ATRIP constructs were washed twice 
with equilibrated phosphate-free DMEM.   Cells were incubated in equilibrated 
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phosphate-free DMEM containing 10% dialyzed FBS for 3 hours.   During this 
time, a betashield box was also placed in the incubator to equilibrate.   To label 
cells, 0.5mCi/mL of 32P-orthophosphate in phosphate-free DMEM containing 
10% dialyzed FBS and 2mM HU was added for 2 hours and dishes placed in the 
betashield box.   Cells were washed once with PBS and 700µL of trypsin added to 
each plate for 5 minutes.  700µL of media was added to trypsinized cells, cells 
were transferred to a 1.5mL screw cap microcentrifuge tube and pelleted at 1000 
rpm for 5 minutes.     Pellets were washed once with PBS and combined into a 
single tube and pelleted.   Cells were lysed in 700µL of TGN lysis buffer 
containing inhibitors for 20 minutes on ice and then cleared at 4oC for 20 minutes 
at 16.1xg.   30µL of protein G agarose (Santa Cruz) and 5µg of mouse IgG were 
added to the cleared lysate for 30 minutes rotating at 4oC.   Protein G agarose was 
pelleted and lysates were transferred to 60µL of HA-beads and rotated at 4oC for 
3 hours.   HA-beads were then washed 3 times with 1mL of RIPA lysis buffer 
(150mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate, 50mM Tris pH 8.0) 
containing inhibitors, 1 time with RIPA buffer containing 500mM LiCl, and 2 
times with RIPA buffer containing inhibitors.    30µL of 2X LSB was added to 
beads and boiled for 10 minutes.   HA-immunoprecipitates were separated by 
SDS-PAGE on an 8% acrylamide gel and transferred to PVDF at 0.2 Amps for 8 
hours.   PVDF membranes were exposed to film for 1 hour to visualize proteins 
with 32P incorporated.   Film was aligned to the membrane, and a syringe was 
used to perforate the membrane around radiolabeled ATR.   Membrane was cut 
and transferred to a 1.5mL centrifuge tube.   1mL of 100% methanol was added 
to the membrane for 1 minute and then removed.   Membranes were washed 
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with 1mL of 0.05M of ammonium bicarbonate containing 0.1% Tween-20 once 
and then incubated in 1mL of the solution for 30 minutes at 37oC.   Membranes 
were washed onced with 1mL of 0.05M ammonium bicarbonate without Tween-
20.  20µL of 0.05M ammonium bicarbonate was added to cover the membrane, 
and 10µL of sequencing grade trypsin (10mg/mL stock, Promega) was added.  
Proteins were digested at 37oC for 3 hours, and another 10µL of trypsin was 
added for an additional 3 hours.   400µL of milliQ water was added to digested 
proteins and dried in a speed vacuum over night.   400µL of milliQ water was 
added to dried samples, vortexed well, and then dried in a speed vacuum for 3 
hours or until completely dry.   Digested proteins were then resuspended in 
400µL of pH 1.9 electrophoresis buffer (2.5% formic acid, 7.8% glacial acetic acid), 
vortexed well, transferred to a new tube, and lyophilized again.  After 
lyophilizing, centrifuge tubes were placed with caps open in a dry scintillation 
vial and 32P was counted in a scintillation counter.   Peptides were resuspended 
in pH 1.9 buffer to equalize counts/volume.   Equal counts were then spotted 
onto cellulose coated glass thin layer chromatography plates according the 
standard protocol (197).   In the case of GST-AAD stimulated maps, counts were 
not equalized.  Instead equal amounts of peptide were spotted.  Plates were 
electrophoresed at 1000V for 30 minutes on a Hunter Box in pH 1.9 buffer and 
then completely dried in the fume hood for several hours.   Plates were then 
transferred to a chromatography tank containing phosphochromatography 
buffer (7.5% glacial acetic acid, 25% pyridine, 37.5% n-Butanol) over night.   
Plates were dried and then exposed to film (197).   
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Cell synchronization 
 To contact inhibit RPE cells, 3.5x106 cells were seeded in a 100mm dish and 
allowed to contact inhibit for 96 hours.   To relieve contact inhibition, cells were 
trypsinized and 3x105 cells were replated in 6 well plates for cell cycle analysis 
 To arrest cells in early S phase, cells were treated with 2mM HU for 24 
hours.   To release cells, HU was removed and cells were washed twice with 
equilibrated media and fresh media containing 1µg/mL nocodazole was added 
to arrest cells in mitosis.    
 To arrest HeLa cells in mitosis, 20ng/mL nocodazole was added to media 
for 18 hours.   Plates were tapped to release mitotic cells and media was 
harvested.   Pellets were washed twice with 50mL of media and replated at 3x105 
cells/6 well in fresh media to release.    
 
Yeast strain construction 
 Strain GA2895 (mec1 Δsml1Δ) was grown to OD600 of 0.5 and pelleted for 2 
minutes at 3000 rpm.   Cells were washed with 5mL of 100mM lithium acetate in 
TE (10mM Tris pH 8.0, 1mM EDTA), pelleted, and resuspended in 1mL of 
100mM lithium acetate in TE.   100µL of yeast was added to a centrifuge tube 
containing 1µg of plasmid.   25µL of boiled salmon sperm ssDNA and 700µL of 
30% PEG-3500/100mM lithium acetate/TE were added to the tube and tubes 
vortexed well.   Tubes were incubated at 30oC for 30 minutes and transferred to a 
42oC water bath for 20 minutes.   Yeast were pelleted for 30 seconds at 3000 rpm 
and supernatant carefully aspirated.   Pellets were resuspended in 150µL of 
sterile water, plated on appropriate plates, and incubated for 2 days at 30oC.  
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Strain genotypes, plasmids used to transform them, and mutagenesis primers are 
summarized in Table 2 and Table 3. 
  
Table 2.  Yeast strains.  Strains used in this study and their genotypes. 
 
Strain Genotype Notes 
GA2895 MATa, ade2-1, trp1-1, his3-11, -15, ura3-1, leu2-3,-112, can1-
100 mec1::HIS3, sml1::KanMX6 
(40) 
yDC208 GA2895 [pRS416: URA3-CEN] pRS416 
yDC209 GA2895 [pRS416:MEC1-URA3-CEN] pBad45 
yDC211 GA2895 [pRS416:E1354R-mec1-URA3-CEN] pDC1141 
yDC212 GA2895 [pRS416:W1359R-mec1-URA3-CEN] pDC1138 
yDC213 GA2895 [pRS416:FRVF1349AAAA-mec1-URA3-CEN] pDC1142 
yEN10 GA2895 [pRS416:HA-MEC1-URA3-CEN] pEN184 
yEN11 GA2895 [pRS416:HA-FRVF1349AAAA-mec1-URA3-CEN] pEN186 
yEN12 GA2895 [pRS416: URA3-CEN] pRS416 
yEN13 GA2895 [pRS426:HA-FRVF1349AAAA-mec1-URA3-2µ] pEN186 
 
 
Table 3.  MEC1 primer sequences.  + denotes a restriction site is added by 
mutagenesis.  – indicates the site is destroyed with mutagenesis. 
 
Primer Sequence Notes 
W1359R 5’-CAGAGTTTTCGAATATTGCAAAAAAGGGCA ACTGAATTTAAACAAAATTACATAAACTAC -PmeI 
E1354R 5’-GAATCCATCTTCAGAGTTTTCAGATATTGCAAA AAATGGGCAACTGAG -BstBI 
FRVF-
AAAA 
5’-CGTTAAGAATGTGCTATGAATCCATCGCC 
GCTGCGGCCGAATATTGCAAAAAATGGGC 
-BstBI 
+EagI 
 
 
 
Yeast western blotting and spot assay 
For Rad53 phosphorylation, logarithmically growing cultures were α-
factor (1pM) arrested for 3 hours at 30oC in YPD pH 3.5.   Arrested cells were 
harvested and washed twice with 1mL of sterile water.   1.0 OD600 of arrested 
cells was treated with 200mM HU for 1 hour at 30oC.   HU-treated cells were 
 51 
pelleted, washed once with 1mL of 20% TCA, and frozen at -80oC.   To lyse, 
200µL of 20% TCA was added to pellets with glass beads and homogenized for 3 
minutes using a bead beater.   Supernatant was transferred to a new tube and 2X 
LSB was added.   Lysates were neutralized with 1M Tris pH 8.0, boiled for 5 
minutes, and cleared for 5 minutes at room temperature at max speed.   Protein 
was quantified using the BioRad Bradford system (samples diluted 1:30) and 
50µg of protein was separated by SDS-PAGE on an 8% acrylamide gel.   A Rad53 
antibody was used at 1:1000 and detected with an anti-rabbit 800 infrared-
conjugated Licor secondary antibody.    
 For western blots of HA-Mec1, cells were homogenized in the presence of 
glass beads and NP-40 buffer 4 times 30 seconds each with 1 minute of rest in 
between.   30µL of HA-beads were incubated with cleared lysates over night at 
4oC and separated by SDS-PAGE on an 8% polyacrylamide gel.   anti-HA 
antibody (Covance) was used at 1:4000 and anti-mouse-HRP conjugated was 
used at 1:10,000.    
 For spotting assays, 5mL of each strain was grown overnight.   1 OD600 of 
cells were transferred to a 1.5mL centrifuge tube and pelletted at 3000rpm for 1 
minute.   The supernatant was removed and cells were resuspended in 200µL of 
sterile water.   200µL of cells were added to the first column of wells in a 96-well 
round bottom plate.   Five 10-fold serial dilutions were made in the adjacent 
columns.   A spotter was used to transfer cells from the 96-wells to pre-warmed 
growth plates.   Plates were dried and then incubated at 30oC until visible 
colonies formed.    
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CHAPTER III 
 
T1989 PHOSPHORYLATION MARKS AN ACTIVE ATR KINASE1 
 
Introduction 
 ATM and DNA-PK, like ATR, are regulated by recruitment to sites of 
DNA damage (169) and by protein activators (170, 173).  In addition, ATM and 
DNA-PK undergo autophosphorylation (162, 181, 184, 198).  These kinases prefer 
to phosphorylate serines or threonines that are immediately followed by 
glutamine (S/TQ).  Phosphorylation sites on ATM and DNA-PK are functionally 
significant and have been used as direct markers of activation (162, 181, 184, 198), 
allowing direct monitoring of ATM and DNA-PK activity in cells.   
ATR autophosphorylates in vitro (36); however, direct evidence for ATR 
regulation by phosphorylation is lacking.  Currently researchers monitor ATR 
activity in cells indirectly through phosphorylation of its substrates.  This is 
problematic for several reasons.  First many ATR substrates, such as RPA, H2AX, 
and p53, are phosphorylated by ATM and DNA-PK.  To address this issue of 
overlapping substrates, investigators monitor Chk1 phosphorylation on S317 and 
S345.  However, ATR-dependent Chk1 phosphorylation has a unique 
requirement for the protein adaptor Claspin.  Therefore, Chk1 phosphorylation 
measures one distinct ATR phosphorylation event that does not necessarily 
reflect ATR activity towards all substrates.  Here I identify and characterize 
T1989 as a DNA damage-regulated ATR phosphorylation site.  T1989 
                                                 
1 A portion of this chapter is published in (191) 
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phosphorylation depends on ATR kinase activity in cells and requires kinase 
activation.   Ablation of T1989 phosphorylation causes a modest functional 
defect.   This is the first characterization of an ATR phosphorylation site that can 
be used as a direct measurement of ATR activity in cells.   
 
Results 
 
ATR T1989 is a DNA damage-induced phosphorylation site 
To identify ATR phosphorylation sites, I purified endogenous ATR-ATRIP 
complexes from hydroxyurea (HU) treated HeLa cells using an anti-ATRIP 
antibody in a single-step immunoprecipitation.  I separated the ATR protein 
from associated proteins by gel electrophoresis and subjected it to in-gel 
digestion followed by liquid chromatography-coupled tandem mass 
spectrometry.  This method identified several ATR phospho-peptides (Table 4), 
including S428, S435 (See Appendix A), and T1989 (Figure 11a).  Several 
phospho-proteomic screens also identified these phospho-residues (125, 126).  
However these groups did not determine how these sites are regulated and 
whether they are functionally significant. 
 
 
Table 4.  List of ATR phosphorylation sites and peptides identified by mass 
spectrometry 
 
Phosphorylation site Peptide 
S428 NLSSNSDGI(p)SK 
S435 RL(p)SSSLNPSK 
S944 SLHS(p)SQMTALPNTPCQNADVR 
T1989 GVELCFPENE(p)TPPEGK 
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T1989 occurs within the ATR FAT domain.  The FAT domain is composed 
of HEAT repeats and is generally highly conserved among ATR orthologues.  
However, sequence alignment revealed that T1989 is only conserved in primates, 
changed to a serine in rodents, and not conserved in frogs or flies (Figure 11b).  
The amino acids flanking T1989 are also poorly conserved. 
 To characterize phosphorylation of T1989 further, I generated a phospho-
peptide specific antibody (pATR).  This antibody recognizes an ATR peptide 
phosphorylated at position T1989 but not the corresponding unmodified peptide 
(Figure 12a).  The antibody also recognizes ATR on immunoblots following 
immunoprecipitation (Figure 12b).  It is specific to ATR, since excision of the 
floxed allele from ATRflox/-TR cells eliminated reactivity (Figure 12b).  Attempts 
to detect phosphorylated ATR by immunoblotting without prior 
immunoprecipitation were unsuccessful due to a cross-reacting protein near the 
same molecular weight as ATR.     
Treating cells with HU increased T1989 phosphorylation (Figure 12c).  
Time-course experiments with HU, ultraviolet radiation (UV), and ionizing 
radiation (IR) revealed increased phosphorylation of T1989 in response to all of 
these agents within one hour of treatment (Figure 12d).  I consistently observed 
the approximately two-fold induction of ATR phosphorylation in cells treated 
with HU for one hour (Figure 12e).  A commonly used marker of ATR activation 
is phosphorylation of the ATR substrate Chk1.  While Chk1 S317 and ATR T1989 
both are phosphorylated within one hour of HU, UV, or IR exposure, Chk1 
phosphorylation did not substantially increase at later times.  In contrast, T1989 
phosphorylation continued to increase at least until 3h after treatment (Figure 
12d).   
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Importantly, lambda phosphatase abolished detection of DNA damage-induced 
T1989 phosphorylation (Figure 12f). 
To determine whether the pATR antibody is specific to phosphorylated 
T1989, I assessed its recognition of an ATR T1989A mutant protein.  In contrast to 
wild-type ATR, the antibody did not recognize an HU-inducible 
phosphorylation on the ATR T1989A protein (Figure 13a).  I did note some 
residual antibody recognition of a protein at the molecular weight of ATR after 
immunoprecipitation of Flag-ATR T1989A (Figure 13a).  To further characterize 
the T1989 dependency of the antibody, we generated ATRflox/-TR cells stably 
expressing Flag-HA-ATR or Flag-HA-ATR T1989A, immunopurified these 
proteins, and blotted with the phosphorylation specific antibody.  In these 
circumstances there was significant recognition of the wild-type protein 
immunoprecipitated from HU-treated cells but no HU-inducible recognition of 
the T1989A mutant (Figure 13b).  I conclude that the antibody is largely specific 
to phosphorylated T1989, and T1989 is hyper-phosphorylated when ATR is 
activated.  The antibody may have some cross-reactivity to another phospho-
epitope on ATR that is not regulated in response to HU.   
 
T1989 phosphorylation depends on ATR kinase activity 
ATM and DNA-PK undergo autophosphorylation, and ATR can 
autophosphorylate in vitro (36).  Most characterized ATM, DNA-PK, and ATR 
phosphorylation sites are S or T followed by Q.  T1989 does not fit this 
consensus; however, there are several characterized ATM and DNA-PK 
autophosphorylation sites that also fail to conform to this consensus sequence 
(180, 199).  Therefore, I tested whether T1989 phosphorylation in cells depends  
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on ATR kinase activity.  First, I assayed whether a kinase-dead ATR mutant can 
be phosphorylated on T1989.  Unlike wild-type ATR, the kinase-dead mutant did 
not exhibit HU-inducible T1989 phosphorylation (Figure 14a).  I next used small 
molecule inhibitors to the PIKK family of kinases.  Selective ATM (KU) and 
DNA-PK (NU) inhibitors did not reduce T1989 phosphorylation following HU 
treatment (Figure 14b).  However, the non-selective ATR and ATM inhibitor 
caffeine significantly decreased T1989 phosphorylation in HU-treated cells and 
inhibited ATR signaling as measured by Chk1 phosphorylation.  Finally, an 
agent that selectively inhibits ATR (AZ20) but not DNA-PK or ATM also 
abrogates HU-induced T1989 phosphorylation on both exogenous (Figure 14c) 
and endogenous ATR (Figure 14d).  These results indicate that T1989 
phosphorylation in cells requires ATR kinase activity. 
Immunopurified ATR-ATRIP complexes failed to phosphorylate a small, 
recombinant ATR fragment containing T1989 purified from E.  coli (not shown).  
We also failed to observe a significant increase in T1989 phosphorylation on 
purified full-length ATR subjected to in vitro conditions that allow 
autophosphorylation (not shown).  Thus, it remains possible that the in vivo 
dependency on ATR kinase activity is due to an ATR-activated kinase rather 
than autophosphorylation.  However, treating cells with a selective Chk1 
inhibitor did not significantly impair HU-induced T1989 phosphorylation 
(Figure 15), indicating that if another kinase is involved, it is not Chk1-
dependent.  While T1989 is followed by a proline like many CDK substrates, 
treatment with the CDK inhibitor roscovitine also had no effect on T1989 
phosphorylation (Figure 15) 
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T1989 phosphorylation requires ATR activation 
ATM and DNA-PK activation and autophosphorylation require their 
protein activators Mre11-Rad50-Nbs1 (MRN) and Ku70/80, respectively (160).  
Thus, I first sought to determine whether T1989 phosphorylation requires the 
ATR activator TopBP1 (109).  Transfection with TopBP1 siRNA alone caused 
increased T1989 phosphorylation even in the absence of a DNA damaging agent.  
This level of phosphorylation did not change upon addition of HU and remained 
below the level seen in HU-treated cells transfected with a control non-targeting 
siRNA (Figure 16a).  I was unable to achieve complete knockdown of TopBP1 in 
these experiments and could still detect significant Chk1 phosphorylation in HU-
treated TopBP1 siRNA cells (Figure 16a).  The incomplete silencing of TopBP1 
expression and increased basal T1989 phosphorylation but lack of HU-inducible 
phosphorylation makes this siRNA experiment difficult to interpret.  As an 
alternative approach, I examined T1989 phosphorylation on the ATR PIKK 
Regulatory Domain (PRD) mutant, which contains the point mutation K2589E.  
This mutation disrupts the ability of ATR to interact with and be activated by 
TopBP1 while retaining basal ATR kinase activity (90).  The ATR-PRD mutant is 
not phosphorylated on T1989 in response to HU (Figure 16b), suggesting that 
T1989 phosphorylation depends on activation of ATR. 
Since T1989 phosphorylation depends on ATR activation, 
phosphorylation is unlikely to be required for the activation process, and an ATR 
T1989A mutant should still be activated by TopBP1 in vitro.  To test this 
hypothesis, I assayed whether the ATR activation domain (AAD) of TopBP1 
could activate immunopurified wild-type, T1989A, and T1989E ATR-ATRIP 
complexes.  All three of these proteins were activated to similar extents by  
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increasing concentrations of the GST-AAD protein but not by GST (Figure 16c).  
A GST-TopBP1 protein containing the AAD and the C-terminal BRCT domains 
of TopBP1 also activated all three proteins (Figure 16d).  Therefore at least under 
these in vitro conditions, T1989 phosphorylation does not impact TopBP1-
mediated ATR activation. 
 
Functional characterization of T1989 phosphorylation   
To examine the functional relevance of T1989 phosphorylation, I 
employed a genetic complementation strategy (Figure 17) using ATRflox/- cells 
harboring one conditional allele of ATR and a second allele disrupted by a 
neomycin cassette (36).  These cells were also engineered to express the 
tetracycline repressor, creating the parental ATRflox/-TR cell line.  I then 
integrated either wild-type (WT) or ATR T1989A mutant expression vectors 
containing a tetracycline-response promoter, creating WT-ATRflox/-TR and 
T1989A-ATRflox/-TR cell lines.  ATR cDNAs also contain an N-terminal Flag-HA3 
epitope tag to differentiate exogenous and endogenous proteins.  After selection, 
I screened stable integrants for inducible expression of the ATR protein and 
selected only clones expressing similar protein levels for further analysis.  In 
addition, I verified that the percentage of cells expressing tagged ATR in each 
clone was similar using immunofluorescence (Figure 18a).  I also confirmed that 
the tagged protein correctly localized to the nucleus and can localize to stalled 
replication forks in response to HU-treatment (Figure 18b).  This analysis 
confirms that the T1989A mutation does not interfere with the ATR-ATRIP 
complex, since ATRIP association is required for both the stability and  
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localization of ATR (36, 84).  In subsequent experiments, I characterized two 
independent mutant cell lines to account for any possible clonal differences. 
 Infecting the parental ATRflox/-TR cells with an adenovirus encoding the 
Cre recombinase nearly ablated ATR protein expression within four days post 
infection (Figure 18c).  Tetracycline-induced expression of the exogenous ATR 
cDNAs restored ATR expression with both WT-ATR and T1989A-ATR expressed 
at similar levels (Figure 18c). 
To compare the signaling activities of the T1989A and WT ATR proteins, I 
deleted the floxed allele, expressed the WT or T1989A mutant, and treated the 
cells with HU.  Deletion of ATRflox in the parental cell line attenuates Chk1 
phosphorylation (Figure 18c, compare lanes 5 and 13).  WT-ATR restored Chk1 
phosphorylation (Figure 18c, lane 14).  Similarly, both T1989A-ATR clones also 
supported ATR-dependent Chk1 phosphorylation (Figure 18c, lanes 15 and 16), 
suggesting T1989 phosphorylation is not required for ATR signaling in response 
to replication stress.   
ATR promotes completion of DNA synthesis following an HU challenge 
(18).  To test whether T1989 phosphorylation regulates this activity, I monitored 
completion of DNA replication following a transient exposure to HU.  After Cre-
deletion of the floxed allele, both WT-ATR and T1989A-ATR cells have similar 
distributions of cells in each cell cycle phase (Figure 18d).  HU synchronizes the 
cells in early S-phase.  Cre-infected parental ATRflox/-TR cells are unable to 
complete S phase when released from the HU arrest.  In contrast, both WT-
ATRflox/-TR and T1989A-ATRflox/-TR cells complete replication with similar 
kinetics (Figure 18d).   
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 ATR is an essential gene required for human cell viability even in the 
absence of exogenous DNA damage (36).  To determine whether T1989 
phosphorylation is required for the essential function of ATR, I grew ATRflox/-TR, 
WT-ATRflox/-TR, and T1989A-ATRflox/-TR cells in the presence of tetracycline, 
infected with adenovirus encoding either GFP or Cre, and allowed single 
colonies to form over a period of 14 days.  I visualized surviving colonies by 
methylene blue staining and counted colonies to determine survival fractions.  
Upon ATR deletion, 5% of AdCre infected parental ATRflox/-TR cells were able to 
form colonies (Figure 19a and b).  Wild-type ATR complements this viability 
defect with 82% of AdCre infected WT-ATRflox/-TR cells forming colonies.  In 
contrast, T1989A-ATR does not fully complement the viability defect caused by 
ATRflox deletion with only 29% and 25% of AdCre infected T1989A-1 and T1989-2-
ATRflox/-TR cells forming colonies respectively. 
I further confirmed the colony formation results by monitoring excision of 
the flox allele in colonies from AdCre infected cells by PCR genotyping.  As 
expected, 100% of colonies (9 out of 9) obtained from the parental ATRflox/-TR cell 
line contained an intact flox allele (Figure 19c).  Thus, they survived only because 
Cre-catalyzed excision was not complete.  In contrast, PCR genotyping showed 
excision of the floxed allele in every colony from AdCre infected WT cells (20 out 
of 20) and in nearly every colony obtained from T1989A-ATRflox/-TR cells (53 out 
of 55).  These results suggest that T1989 phosphorylation may be important but 
not essential for ATR to support cell viability.   
Because the T1989A-ATR protein yielded a modest colony formation 
defect, I considered the possibility that a mild checkpoint signaling defect may 
not have been observed in the Cre infection experiments (Figure 18c) due to  
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residual endogenous ATR protein expression following Cre-mediated excision of 
the flox allele.  To address this possibility, WT and T1989A AdCre infected 
colonies determined to have an excised flox allele by PCR genotyping were 
expanded, creating WT-ATRdel/-TR and T1989A-ATRdel/-TR cell lines that have no 
intact ATR genes at the endogenous loci.  I confirmed that the only ATR 
expressed in these cell lines comes from the integrated ATR wild-type or T1989A 
cDNAs (Figure 20a) and that the percentage of S phase cells was similar among 
cell lines (Figure 20b).  I examined Chk1 phosphorylation in two WT-ATRdel/-TR 
and six T1989A-ATRdel/-TR clones with varying levels of ATR expression.  
T1989A ATR expression varied between 37% (T1989A2.2) and 122% (T1989A1.3) 
of the ATR level in the parental ATRflox/-TR cells.  For comparison, WT1.1 and 
WT1.2 expressed ATR at 80% and 64% of the ATRflox/-TR expression level.  Both 
WT clones supported Chk1 phosphorylation equally (Figure 21a).  The amount of 
Chk1 phosphorylation varied in the T1989A-ATRdel/-TR cell lines (Figure 21a) 
and correlated with the amount of T1989A protein expressed (Figure 21b).  The 
cell lines expressing the least amount of T1989A protein exhibited approximately 
60% of wild-type Chk1 phosphorylation while cell lines expressing the most 
T1989A had 150% of wild-type Chk1 phosphorylation levels.  Thus, I conclude 
that the T1989A-ATR protein signals to phosphorylate Chk1 as efficiently as 
wild-type ATR when expressed at similar levels. 
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Discussion 
A challenge to studying ATR function has been the lack of a proximal 
biomarker to detect an active ATR kinase.  Thus, researchers use Chk1 
phosphorylation as a surrogate.  However, ATR-dependent Chk1 
phosphorylation requires proteins like Claspin that are not necessary for ATR to 
phosphorylate other substrates (133).  There may also be instances in which Chk1 
is phosphorylated by other kinases like ATM.  My data on T1989 
phosphorylation suggests it is a good biomarker for active ATR.  T1989 
phosphorylation is DNA damage-regulated, depends on ATR kinase activity, 
appears concurrently with ATR-dependent phosphorylation of Chk1, and 
requires activation of the ATR kinase.  Functionally, T1989 phosphorylation is 
not essential for the ATR-Chk1 signaling axis following replication stress but has 
some function in supporting cellular viability.   
 
Regulation of T1989 phosphorylation 
My cellular data indicate that T1989 phosphorylation requires ATR kinase 
activity suggesting it may be an autophosphorylation site.  While T1989 does not 
conform to the typical ATR S/TQ phosphorylation consensus, there is 
precedence for nonconsensus ATM and DNA-PK autophosphorylation.  Several 
DNA-PK autophosphorylation residues in the PQR cluster are tyrosine-directed 
(183), and ATM autophosphorylation sites S1893 (181) and S2996 (180) are 
glutamic and aspartic acid-directed respectively.  I was unable to obtain evidence 
that T1989 is phosphorylated by ATR in vitro.  However, these experiments are 
done in conditions that do not fully reconstitute the ATR activation mechanism, 
and two-dimensional phospho-peptide maps of in vivo and in vitro ATR 
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phospho-peptides have minimal similarities (Figure 31b-c).  Thus, it is unclear 
whether the in vitro ATR kinase analysis mimics what happens in vivo.  The other 
possibility is that an ATR-dependent kinase phosphorylates T1989.  Only Chk1 is 
a well-defined ATR-dependent kinase, but my experiments indicate it is not 
required for T1989 phosphorylation.   Further analyses will be necessary to 
unambiguously determine whether T1989 is truly an autophosphorylation site or 
phosphorylated by an ATR-activated kinase in an autoregulatatory circuit.    
I noted that Chk1 phosphorylation remains constant after reaching a high 
level 1h after HU treatment whereas ATR T1989 phosphorylation continued to 
increase throughout the HU time course.  The source of the difference is 
presently unclear but could be explained if different phosphatases act on these 
sites to cause the dynamic differences.  Alternatively, it may take longer for most 
ATR molecules in the cell to be activated compared to Chk1 molecules.   Future 
studies examining the timing and persistence of T1989 phosphorylation will help 
answer some of these questions.   In addition, genetic and inhibitor experiments 
may reveal whether phosphatases regulate T1989 phosphorylation.    
Mutation of the ATR PRD, which prevents TopBP1-dependent ATR 
activation (90), abolishes DNA damage-induced T1989 phosphorylation.  Thus, 
T1989 phosphorylation requires ATR activation and suggests this site is 
downstream of TopBP1 function.  Likewise, autophosphorylation of ATM and 
DNA-PK also requires activation by their protein activators (184, 200, 201).  
Though the only known function of the ATR PRD is to facilitate ATR activation 
by binding TopBP1, I cannot exclude the possibility that proteins other than 
TopBP1 function through the PRD to promote T1989 phosphorylation.   It will be 
interesting to further probe the dependency of T1989 phosphorylation on other 
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known steps of ATR activation, namely the Rad9-Hus1-Rad1 complex.   In 
mammalian cells, the 9-1-1 complex promotes TopBP1 recruitment.   Based on 
PRD mutant data, I hypothesize that T1989 phosphorylation would also depend 
on the 9-1-1 complex.   However, evidence in Xenopus suggests that there are 
modes of 9-1-1 independent recruitment for TopBP1.  
Ablation of the ATM autophosphorylation site S1981 does not impact 
MRN-mediated activation of ATM (171).  Similarly, mutation of T1989 to an 
alanine does not perturb TopBP1-mediated activation of ATR in vitro.  Also in 
agreement with a lack of an ATR activation defect is the absence of strong 
signaling and functional defects in cells expressing only the unphosphorylatable 
T1989A ATR protein.  ATR mutations that disrupt the activation process, such as 
the K2589E PRD mutant, exhibit severe cellular defects due to their inability to be 
activated (90).   
Chk1 phosphorylation in multiple T1989A-ATRdel/-TR cell lines showed a 
strong correlation with ATR protein levels.  When T1989A ATR is expressed at 
levels similar to those found in ATRflox/-TR cells, it signals to Chk1 similar to 
wild-type ATR.   ATR protein levels in the ATRflox/-TR cells is approximately 30-
40% of that found in the ATR+/+ cell line due to the deletion of one ATR allele and 
the insertion of the loxP sites in the remaining expressed allele.  Thus, the lack of 
an obvious ATR signaling defect in the T1989A mutant cell lines is not due to 
over-expression of this protein.   
Despite the lack of a signaling defect, I observed a significant albeit partial 
decrease in the ability of T1989A ATR to maintain cell viability when challenged 
in a colony formation assay.  A possible explanation is that T1989A ATR is 
expressed at variable levels in the clonal population.  Low expression levels may 
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not support viability, since signaling under these circumstances is attenuated 
compared to cells with wild-type expression levels.  The viability assay likely 
presents a stringent requirement for ATR function, since it requires colony 
growth from a single cell.  However once the T1989A-ATRdel/-TR cells that 
survived were expanded, they showed no evidence of a continued survival or 
proliferation deficit, indicating T1989 is not essential for ATR function.  The low 
conservation of T1989 even among vertebrate ATR orthologues and the lack of 
salient activation and signaling defects corroborate this conclusion.   
The modest phenotypic consequence of the T1989A mutation is 
reminiscent of single mutants of DNA-PK autophosphorylation clusters (202).  
Mutation of multiple sites across clusters (203) or of a single cluster in entirety 
(202)  is required to observe strong defects.  Disruption of additional ATR 
phosphorylation sites may be needed to produce a significant biological defect.  
The functional significance of T1989 phosphorylation may also depend on 
specific cellular contexts.  For instance, mutation of ATM S1981 to an alanine 
results in functional defects in human cells (162), yet there is no functional 
consequence of mutating this phosphorylation site in mouse cells (185).   
 
Mechanistic implications of T1989 phosphorylation 
Mechanistically it is difficult to hypothesize how T1989 phosphorylation 
may regulate ATR activity.   I have strong evidence supporting that T1989 
phosphorylation occurs after TopBP1-mediated activation and that T1989 is not 
essential for Chk1 phosphorylation in cells.   Therefore, one possibility is that 
T1989 phosphorylation is not necessarily regulatory.   ATR oligomerizes (204) 
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and the FAT domain where T1989 resides is adjacent to the kinase domain.  
Active ATR molecules may autophosphorylate in trans due to proximity.   
However, cells expressing the T1989A mutant exhibited a modest viability 
defect, suggesting T1989 phosphorylation is functional.   The ATR FAT domain, 
is thought to interact with the FATC domain to stabilize the intervening kinase 
domain.   The FAT domain of DNA-PK also undergoes a considerable 
conformational shift upon kinase activation (182).   T1989 phosphorylation may 
serve to further stabilize the complex after activation and function in signal 
amplification.   Under conditions of exogenous stress where many ATR kinase 
molecules are activated, signal amplification may not be as critical to maintain 
signaling.   During normal unperturbed rounds of replication where fewer 
molecules of ATR are activated such a mechanism may become important.    
 
Research and Clinical Applications 
 Since T1989 is a damage-regulated phosphorylation site that requires 
activation of ATR, antibodies to this phosphorylation site will be useful to 
directly monitor an active ATR kinase in cells.  In addition to facilitating future 
research on ATR function, monitoring ATR T1989 phosphorylation may also 
prove to be a useful biomarker for cancer treatment or as a measurement of 
oncogene-induced replication stress.   For instance, many current therapies cause 
DNA replication stress and several groups have developed ATR-selective 
inhibitors for potential use in the clinic (205, 206).   Monitoring T1989 
phosphorylation in tumors may prove to be a predictive marker for treatment 
response and could be used to assess inhibition of ATR signaling after treatment.  
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CHAPTER IV 
 
ANALYSIS OF MUTATIONS THAT DISSOCIATE G2 AND ESSENTIAL S 
PHASE FUNCTIONS OF HUMAN ATR 
 
Introduction 
 In the previous chapter, I tested the hypothesis that phosphorylation 
regulates ATR activity using mass spectrometry to identify ATR T1989 as a DNA 
damage-regulated phosphorylation site.   It remains unclear whether ATR T1989 
is an autophosphorylation site.   However ATR autophosphorylates in vitro, 
suggesting ATR S/TQ consensus residues may be autophosphorylation sites.   In 
this chapter, I test whether these candidate autophosphorylation sites are 
required for ATR function. 
ATR contains 16 conserved candidate autophosphorylation sites that 
match the S/TQ consensus.   A 16A-ATR mutant protein, which contains all 16 
sites mutated to alanine, maintains kinase and G2 checkpoint activities.   
However, it fails to rescue the essential function of ATR in maintaining cell 
viability and fails to promote replication recovery from a transient exposure to 
replication stress.  Further analysis identified T1566A/T1578A/T1589A (3A-
ATR) as critical mutations causing this separation of function activity.   
Secondary structure predictions indicate these residues occur in a region 
between ATR HEAT repeats 31R and 32R.   This region aligns with regions of 
ATM and DNA-PK containing regulatory autophosphorylation sites.  It is 
unclear if ATR also autophosphorylates in this region.   Nevertheless, my 
analysis identifies an important regulatory region of ATR that is shared among 
the DNA damage response PIKK kinases.   Furthermore, my data indicates that 
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the essential function of ATR is linked to its function in promoting proper 
replication in the context of replication stress and is independent of G2 
checkpoint activity. 
 
Results 
 
Identification of an ATR separation of function mutant   
Human ATR contains 19 putative autophosphorylation consensus sites 
(S/TQ).  Primary sequence alignment of ATR orthologs revealed conservation of 
16 of these residues to mouse with several conserved to X.  laevis and S.  cerevisiae 
(Figure 22a).   To examine their functional significance, I mutated the 16 
conserved residues to alanine within a single cDNA, generating a 16A-ATR 
mutant.    
I characterized the 16A-ATR mutant in the same genetic complementation 
assay used to examine ATR T1989 phosphorylation (Figure 17).   This assay 
utilizes the parental cell line ATRflox/-TR, which harbors a conditional ATR allele, 
a second ATR allele disrupted by a neomycin cassette, and a stably integrated 
construct expressing the tetracycline repressor (TR) (90).   I then integrated either 
wild type (WT) or 16A-ATR constructs with a tetracycline response promoter, 
creating WT-ATRflox/-TR and 16A-ATRflox/-TR cell lines.   ATR cDNAs also contain 
an N-terminal Flag-HA3 epitope tag to differentiate exogenous and endogenous 
proteins.   I screened stable integrants for equal protein levels and verified that 
percentages of cells expressing tagged ATR were similar among clones.   I 
characterized at least two independent mutant clones in subsequent experiments 
to account for possible clonal differences.    
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I induced expression of integrated ATR alleles and infected cell lines with 
adenovirus expressing Cre recombinase (AdCre) to delete the ATRflox allele or 
GFP (AdGFP) as a control.   96 hours post infection, excision of ATRflox in parental 
ATRflox/-TR cells caused a substantial reduction in ATR protein levels (Figure 22b 
lanes 1 vs. 6).   The integrated WT-ATR or 16A-ATR cDNAs express at 
comparable levels (Figure 22b, lanes 8-10), which is similar to the amount 
expressed from the endogenous locus in the heterozygous ATR+/- cells lacking a 
flox allele. 
To test the proficiency of 16A-ATR to prevent progression into mitosis 
after DNA damage, I performed a G2 checkpoint assay.   After tetracycline 
induction and adenovirus infection, I treated uncomplemented parental, WT-, 
and 16A-ATRflox/-TR cells with ionizing radiation (IR) and cultured cells in 
nocodazole to block cells in mitosis.   I determined the mitotic index by 
quantification of phospho-Ser10 Histone H3 positive cells using flow cytometry.   
Following deletion of the ATRflox allele, 37% of uncomplemented, parental 
ATRflox/-TR cells progressed into mitosis after IR treatment.   However, only 13% 
of WT-ATR integrants and 15% and 13% of the two 16A-ATR integrants entered 
mitosis post-IR (Figure 22c).   These results demonstrate that 16A-ATR is 
proficient in maintaining the G2 checkpoint.    
Since ATR is essential for cellular viability in mammalian cells even in the 
absence of DNA damage, I examined the ability of 16A-ATR to support viability 
using a colony formation assay.   I induced expression of integrated ATR 
constructs, infected cells with AdGFP or AdCre, and allowed single colonies to 
form over a period of 14 days.   32% of the parental ATRflox/-TR cells formed 
colonies upon ATRflox deletion (Figure 22d) while expression of WT-ATR  
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significantly improved viability with 72% of cells forming colonies.   As 
previously reported, the surviving colonies of the parental ATRflox/-TR cell line 
are due to incomplete Cre-excision of the flox allele (Figure 22e) (36).   Unlike the 
WT-ATR cells, only 25% and 30% of cells in the two 16A-ATR cell lines formed 
colonies (Figure 22d).    
Only 1 in 8 of the surviving 16A-ATR colonies from AdCre-infected cells 
actually successfully deleted the ATRflox allele (Figure 22e).   Thus, most of the 
surviving colonies of 16A-ATR cells grew because they maintained expression of 
the endogenous wild-type ATR allele.  In contrast, 5 of 5 colonies tested from the 
AdCre-infected WT-ATR cell line contained a deleted flox allele and only express 
the integrated WT-ATR cDNA.  Thus, the 16A-ATR protein has a significantly 
diminished capacity to maintain cell viability after deletion of the endogenous 
ATR alleles.  These data together with G2 checkpoint results indicate that 16A-
ATR acts as a separation of function mutant. 
 
16A-ATR mutations result in replication stress response defects.    
The mec1-100 allele of S.  cerevisiae ATR is a separation of function mutant 
defective in S but not G2 checkpoint functions (207).   Thus, I hypothesized that 
reduced viability but G2 checkpoint proficiency of 16A-ATR may be due to a 
separation of human ATR functions in S and G2 phases.   To examine S phase 
functions, I investigated if 16A-ATR could support resumption of DNA synthesis 
following a transient exposure to replication stress.  I treated WT- and 16A-
ATRdel/-TR cells with hydroxyurea (HU) for 24 hours, removed the HU, and 
monitored DNA content.  16 hours after release from HU, WT-ATR cells 
proceeded through S phase and accumulated with 4N DNA content, since I 
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added nocodazole to the release media.   However, a large portion of 16A-ATR 
cells did not complete replication upon release (Figure 23a), demonstrating 16A-
ATR does not support the completion of DNA synthesis after a transient 
replication block.   
In agreement with a replication stress response defect, 16A-ATR has a 
reduced ability to phosphorylate Chk1 in HU-treated cells (Figure 23b).   
Quantification of three independent experiments confirmed a 50% reduction that 
is reproducible and statistically significant (Figure 23c).  This 16A-ATR signaling 
defect was not due to a difference in the number of cells in S phase, since BrdU 
incorporation indicated that 55% of WT-ATRdel/-TR and 53% of 16A-ATRdel/-TR 
cells were in S phase at the time of HU addition.   These observations further 
indicate that the 16A mutation separates G2 and S phase functions of ATR.    
16A-ATR defects could be due to changes in protein folding or stability.   
However, I did not detect a difference in protein stability or basal kinase activity 
(Figure 24a and b).   16A-ATR mutations also did not disrupt the ability of ATR 
to form higher order oligomers (Figure 24c) further suggesting it is properly 
folded.   Finally, both WT and 16A-ATR localized to stalled replication forks 
(Figure 24d and e), which depends on an interaction with ATRIP.   The 16A-ATR 
mutations actually reproducibly increased TopBP1-stimulated in vitro ATR 
kinase activity compared to WT-ATR (Figure 24f).   However, this phenotype 
does not segregate with the minimal ATR mutations causing viability and 
replication stress response defects (see 3A-ATR below).   These results indicate 
that the functional defects of the 16A-ATR protein in cells are not due to a defect 
in protein folding, stability, or interaction with protein partners. 
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S944 
 In the mass spectrometry analysis conducted in Chapter III, I identified 
one ATR phospho-peptide, SLHS(p)SQMTALPNTPCQNADVR, that potentially 
is phosphorylated at S944.   However, there are several potential phospho-
accepting residues in the peptide, and I did not obtain sufficient peptide 
fragmentation in subsequent mass spectrometry scans to unequivocally assign 
the identity of the modified residue.   In addition to the mass spectrometry data, 
S944 is conserved in H.  sapiens, M.  musculus, and X.  laevis, suggesting it may be 
functionally important.   To test its functional significance, I generated WT-
ATRdel/-TR and S944A-ATRdel/-TR cell lines that only express the integrated forms 
of ATR (Figure 25a) and examined DNA synthesis completion following a 
transient exposure to HU.   Both WT and S944A cells completed DNA synthesis 
upon release from HU (Figure 25b), indicating that S944 is not required for S 
phase functions of ATR. 
 
S2143 
 Of the sixteen conserved candidate ATR autophosphorylation sites, only 
S2143 is conserved in H.  sapiens, M.  musculus, and X.  laevis and changed to a 
threonine in S.  cerevisiae.   Because this residue is highly conserved, I also 
examined its functional significance by assaying the ability of S2143A-ATRdel/-TR 
cells (Figure 26a) to complete DNA replication after a transient exposure to HU.    
S2143A expressing cells completed DNA synthesis after HU release similar to the 
WT-ATR expressing cell line (Figure 26b).   Therefore S2143 is also dispensable 
for ATR function in S phase. 
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3A-ATR phenocopies 16A-ATR replication stress response defects 
To determine which of the 16 mutations within 16A-ATR cause the 
functional defects, I analyzed mutants containing a subset of the 16A mutations 
in the cellular complementation assay.   First, I generated two mutants 
containing either the 4 N-terminal sites (Figure 22a; 4N-ATR) or the remaining 12 
C-terminal sites mutated to alanine (Figure 22a; 12C-ATR) and integrated the 
mutant cDNAs into the ATRflox/-TR cell line.   I screened mutant cell lines as 
before and determined the protein levels to be at least equal to wild type 
expressing cells (Figure 27a).   Colony formation assays revealed that two 4N-
ATR expressing clones complemented the essential function of ATR similar to 
WT-ATR (61% and 51% viable 4N-ATR colonies compared to 64% WT).   
However, both 12C-ATR expressing clones exhibited significantly reduced 
viability (26% and 9%) in the colony formation assay (Figure 27b).    
 Further analysis identified a triple mutant, T1566A/T1578A/T1589A (3A-
ATR), that phenocopies the reduced viability observed in the 16A-ATR mutant.   
Only 21% and 25% of cells from two independent 3A-ATRflox/-TR cell lines 
formed colonies after excision of the flox allele compared to 80% of WT-ATRflox/-
TR cells despite similar protein expression (Figure 27c and d).   Slight differences 
in colony formation by the parental ATRflox/-TR cell line in Figure 27 is likely due 
to differences in adenovirus batch used to delete the floxed allele.   However, 
within each group of experiments, the colony formation efficiencies were highly 
reproducible.   PCR genotyping confirmed the reduced viability of the 3A-ATR 
clones after Cre-mediated excision of the ATRflox allele.   12 of 14 colonies from 
Cre-infected WT-ATR colonies contained a deleted flox allele compared to only 6 
of 21 3A-ATR expressing clones.    
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 I next examined whether 3A-ATR also recapitulates 16A-ATR replication 
stress response defects.   Three independent clones of 3A-ATR cells exhibited 
reduced Chk1 and SMC1 phosphorylation after HU treatment compared to WT 
(Figure 28a).   BrdU incorporation assays showed that this difference in 
phosphorylation cannot be explained by differences in the percentage of S phase 
cells among clones at the time of the experiment (%BrdU positive:  WT1 49%, 
WT3 52%, 3A1 49%, 3A2 44%, and 3A3 42%). 
3A-ATR mutations also compromised completion of DNA synthesis 
following a transient replication block.   Only 22%, 21%, and 22% of WT-ATR 
cells in three independent cell lines did not complete DNA synthesis 16 hours 
after HU removal while 36%, 49%, and 39% of the 3A-ATR cells failed to 
complete replication at the same time point (Figure 28b).   In agreement with the 
16A-ATR results, the G2 checkpoint also remained intact in the 3A-ATR mutant 
(Figure 28c).   Together, these data confirm that the reduced viability observed in 
3A-ATR cells correlates with a defect in S phase but not G2 checkpoint functions 
of ATR similar to the 16A-ATR phenotype.   I also measured TopBP1-mediated 
activation of 3A-ATR and found it was similar to WT-ATR (Figure 28d).   
Therefore the increased in vitro ATR activation observed with the 16A-ATR 
mutations does not segregate with the viability and S phase defects. 
ATR-dependent Chk1 phosphorylation requires the adaptor protein 
Claspin, which interacts with ATR.   The requirement for Claspin in Chk1 
phosphorylation is unique to Chk1.   I examined whether 3A-ATR mutations 
disrupt the ATR-Claspin interaction by Flag-immunoprecipitating ATR from 
293T cells transiently expressing Flag-WT, Flag-16A, and Flag-3A forms of ATR.   
Claspin co-immunoprecipitated with all three forms of Flag-ATR (Figure 29).    
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This indicates that the reduction in Chk1 phosphorylation observed in 16A and 
3A-ATR mutants is not due to a defect Claspin binding.   This is in agreement 
with the reduction in SMC1 phosphorylation, which does not require Claspin, in 
3A-ATR expressing cells. 
 
A conserved extended inter-HEAT repeat loop is important for ATR function    
Due to the functional defects observed with 3A-ATR, I was curious about 
the domain architecture surrounding the mutated residues.   The PIKK kinases 
consist of a large number of helical HEAT repeats.   A HEAT repeat consists of 
two anti-parallel helices.   These HEAT repeats are connected by inter-HEAT 
repeat loops to form the large array of repeats found in PIKKs.   While the 
primary sequence of ATR and ATM HEAT repeats differ, Perry and Kleckner 
aligned the two proteins by the secondary structure of these repeats.   According 
to the HEAT repeat alignments designated by Perry and Kleckner (165), 3A-ATR 
residues occur in the inter-HEAT repeat loop between ATR HEAT repeats 31R 
and 32R (amino acid (aa) 1557-1628) and is just N-terminal to the FAT domain 
(aa1640) (Figure 30).   Notably while inter-HEAT repeat loops are typically short 
5-20aa linkers, the loop between 31R and 32R is 71aa long and predicted to be 
largely unstructured except for a short predicted helix.    
ATR HEAT repeats 31R and 32R align with ATM HEAT repeats 34M and 
35M  (Figure 30)(165).   Similar to ATR, the inter-HEAT repeat loop between 34M 
and 35M (aa1875-1927) is longer than a typical inter-HEAT repeat loop (52aa), 
predicted to be unstructured except for a single helix, and is just N-terminal of 
the ATM FAT domain (aa1960).   Importantly, this region contains the regulatory 
ATM autophosphorylation site S1893 whose mutation to alanine results in  
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radiosensitivity and loss of checkpoint activity (181).   Secondary structure 
predictions of DNA-PK also reveal the presence of an extensive 158aa inter-
HEAT repeat loop (aa2566-2723) N-terminal to the DNA-PK FAT domain that 
contains the regulatory ABCDE (T2609/S2612/T2638/T2647) 
autophosphorylation cluster (Figure 30) (184, 198).   These similarities suggest 
that the region between ATR 31R and 32R is a conserved regulatory region 
among the DNA damage PIKKs, and several of these sites may be targeted for 
autophosphorylation. 
 
Phospho-peptide analysis of ATR mutants 
I analyzed purified ATR from undamaged and HU-treated cells for 
phosphorylation by mass spectrometry but was unable to detect a modified 
peptide containing T1566, T1578, or T1589 despite multiple attempts.   This mass 
spectrometry analysis was limited by our ability to detect peptides spanning this 
region.   I next assayed autophosphorylation of WT and 3A-ATR in vitro.   I Flag-
immunoprecipitated ATR from cells expressing Flag-WT or Flag-3A-ATR and 
allowed ATR to autophosphorylate.   32P incorporation was comparable between 
WT and 3A-ATR (Figure 31a), suggesting 3A-ATR mutations do not diminish 
ATR autophosphorylation under these in vitro conditions.    
I reasoned that analysis of 32P incorporation into total ATR proteins may 
not be sensitive enough to detect loss of one or a few phospho-residues if there 
are many other autophosphorylation sites within ATR.   I also postulated that 
phosphorylation of 3A-ATR residues may require TopBP1-mediated ATR 
activation.   To address both of these considerations, I examined ATR phospho-
peptides under conditions that included TopBP1-mediated ATR activation.    
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I purified ATR-ATRIP complexes from cells expressing Flag-ATR and HA-
ATRIP constructs and allowed ATR to autophosphorylate in the presence of 
recombinant GST or GST-TopBP1 ATR activating domain (GST-AAD) in vitro.   I 
separated kinase reactions by SDS-PAGE, excised the ATR bands incorporating 
32P, generated phospho-peptides by trypsin digestion, and compared phospho-
peptides of WT and 3A-ATR using two-dimensional thin layer chromatography 
(2D-TLC) phospho-peptide mapping. 
Comparison of WT and 3A-ATR phospho-peptides from GST maps did 
not reveal loss of a detectable phospho-peptide (Figure 31b compare top panels), 
although there is small variability in intensity of some phospho-peptides.   Upon 
GST-AAD addition, one relatively low abundance phospho-peptide appeared 
(Figure 31b, asterisk in bottom panels).     GST-AAD addition to 3A-ATR also 
induced this phospho-peptide.   Therefore under these conditions, 3A-ATR 
mutations fail to eliminate a discernible phospho-peptide. 
I also examined in vivo ATR phospho-peptides obtained from HU-treated 
32P metabolically labeled cells transiently overexpressing Flag-HA3-WT or Flag-
HA3-16A-ATR.   I did not observe loss of an in vivo phospho-peptide with 16A-
ATR mutations (Figure 31c).   Of note, the in vivo and in vitro WT-ATR phospho-
peptide maps are dissimilar (compare maps in Figure 31b and c).   The in vivo 
maps will include phosphorylation sites catalyzed by other kinases, which likely 
explains some of the difference.  However, these results also indicate that in vitro 
and in vivo phosphorylation may be different.    
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T1589 is important for ATR function 
While I could not determine the phosphorylation status of T1566, T1578, 
and T1589, my data suggests they are important for ATR function.   I next sought 
to determine if any of these sites alone were sufficient to disrupt ATR function.   I 
created T1566A-ATRflox/-TR, T1578A-ATRflox/-TR and T1589A-ATRflox/-TR cell 
lines to examine the functional significance of each residue in the 3A-ATR 
mutant.   Upon deletion of the floxed allele, WT-ATR and two T1578A-ATR 
expressing cell lines formed similar numbers of colonies (Figure 32a and b).   One 
T1566A-ATR expressing cell line supported colony formation after deletion of 
ATRflox; however the second cell line did not (Figure 32b).   Therefore, it is 
inconclusive whether T1566 impacts viability.    
To confirm viability results, I also analyzed DNA replication following 
HU exposure in WT-ATRdel/-TR, T1578A-ATRdel/-TR, and T1566A-ATRdel/-TR cell 
lines.   After removal of HU, a similar percent of WT, T1578A, and T1566A 
expressing cells persisted with less than 4N DNA content (Figure 32c).   These 
results support that mutation of T1578 alone cannot recapitulate replication 
stress response and viability defects observed in the 3A-ATR mutant.   Also the 
lack of a replication stress response defect in T1566A-ATRdel/-TR cell lines suggest 
that the viability defect observed in one cell line may be clonal and that mutation 
of T1566 alone also is not sufficient to recapitulate 3A-ATR phenotypes.    
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While the point mutants T1566A and T1578A were not sufficient to cause 
viability and replication stress response defects, mutation of T1589 to alanine 
resulted in viability defects (Figure 33 a and b).   In addition, three independent 
T1589A-ATRdel/-TR cells exhibited replication stress response defects (Figure 33c).   
These data indicate that mutation of T1589 alone is sufficient to cause viability 
and replication stress response defects.   A T1589E mutant also could not rescue 
viability (not shown).  I examined ATR mutants for T1989 phosphorylation after 
HU treatment and did not detect a difference (Figure 34). 
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Discussion 
My data demonstrate that the S and G2 phase functions of ATR can be 
separated by mutation of three candidate ATR autophosphorylation sites, 
T1566/T1578/T1589, within an S/TQ cluster.   Based on HEAT repeat 
alignments, the mutated residues occur in a region of ATR that aligns to regions 
of ATM and DNA-PK containing functional autophosphorylation sites, although 
I have been unable to demonstrate ATR autophosphorylates any of these 
residues.   ATR is essential for viability, promotes recovery from replication 
stress, and activates the G2 DNA damage checkpoint.   Mutation of 3A-ATR 
residues perturbs viability and replication stress responses but not the G2 
checkpoint.   This is the first identification and characterization of a separation of 
function mutant in human ATR that dissociates S and G2 phase activities.   The 
correlation between cell viability and S phase defects suggests that the essential 
function of ATR is to promote completion of DNA replication.    
 
ATR phosphorylation 
 Incomplete peptide coverage of ATR hindered detection of 
phosphorylation by mass spectrometry.   I also did not detect loss of 
phosphorylation in phospho-peptide maps.   These maps were generated using 
transiently overexpressed ATR, which may not be regulated the same as the 
endogenous protein.   Indeed, Sancar and colleagues reported that they could 
only reconstitute ATR signaling in vitro by purifying endogenous, not 
overexpressed ATR complexes (208).   I attempted to analyze phospho-peptides 
of endogenous ATR but was unable to obtain sufficient quantities of purified 
labeled protein.    My in vivo phospho-peptide maps do suggest that there are 
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multiple regulatory phosphorylation sites on ATR.   Identification of these 
phosphorylation sites will be necessary to understand the function of ATR 
phosphorylation.    
 The in vitro kinase activity of 3A-ATR is indistinguishable from WT-ATR.   
However, 3A-ATR does not phosphorylate Chk1 or SMC1 as well as the wild-
type protein in cells.   This observation is similar to the S1981A-ATM 
autophosphorylation mutant, which has in vivo but not in vitro substrate 
phosphorylation defects (162).   Likewise, DNA-PK autophosphorylation 
mutants also do not show in vitro phosphorylation defects (202).    
Mutation of a single site, T1589, is sufficient to cause viability defects.  The 
inability of T1589E-ATR to rescue viability defects may indicate that the 
threonine residue and not phosphorylation is critical at this position.   This has 
been implicated to be true for several putative phosphorylation sites in human 
Claspin (209).   However, a glutamic acid may not effectively mimic 
phosphorylation, or constitutive phosphorylation may be detrimental to protein 
function.   Phospho-mimicking mutations of DNA-PK ABCDE 
autophosphorylation sites in the analogous 3A-ATR region only partially rescue 
function (202).   Phospho-specific antibodies generated against a phospho-
peptide did not react with ATR in a T1589 dependent manner.   Thus, it remains 
to be determined whether T1589 is an ATR phosphorylation site.   
 
Separation of Essential S phase functions of ATR from G2 checkpoint activity  
In S.  cerevisiae, MEC1ATR deletion results in inviability in the absence of 
exogenous DNA damage (210).   Deletion of SML1, which suppresses nucleotide 
production via inhibiting ribonucleotide reductase1 subunit (Rnr1), rescues 
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MEC1 deletion (211) (212).   Overexpression of Rnr1 also suppresses Mec1 
deficiency (158), suggesting the essential function of Mec1 is to regulate 
nucleotide levels.   However, SML1 deletion does not rescue DNA damage 
sensitivity caused by MEC1 deletion (212).    
ATR deletion in mammalian cells also results in embryonic lethality.   
While nucleotide production is cell cycle regulated in human cells as well, DNA 
damage does not cause an increase in nucleotide levels (213).  There is no 
evidence that ATR regulates nucleotide production in human cells or that ATR-
deficiency can be rescued by increasing nucleotide levels.   Thus, the essential 
function of ATR in human cells has been unclear.   Nucleotide production in 
yeast occurs de novo while a nucleotide salvage pathway also exists in 
mammalian cells (214).   This redundancy may explain why a clear link between 
nucleotide regulation and ATR function has not been made.   My data suggest 
that the essential function of human ATR is to promote completion of DNA 
synthesis after a challenge to replication.   The exact functions of ATR in S phase 
that are disrupted by 3A-ATR mutations remain unclear.    
3A-ATR mutations cause defects in viability but only a 50% reduction in 
signaling to Chk1 and SMC1.   A 50% reduction in phosphorylation may be 
sufficient to cause viability defects especially considering other ATR substrates 
are likely to be affected as well.   Gene dosage is known to be important for ATR 
function.   ATR is a haploinsufficient tumor suppressor in certain genetic 
backgrounds (215, 216), and reducing ATR protein levels can sensitize tumor cell 
lines to chemotherapies (217).   Additionally, a hypomorphic allele of ATR found 
in Seckel Syndrome patients results in diminished ATR protein levels due to 
aberrant splicing (53, 54).   
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 Why might low levels of ATR signaling be insufficient for cell viability 
and the replication stress response but sufficient for the G2 checkpoint?  
Redundancy in signaling is a likely explanation.   ATM, DNA-PK, and ATR 
signal in response to DNA double strand breaks (DSB) or resected DSBs in the 
case of ATR.   Reducing the contribution of ATR in checkpoint signaling 
following DSB generation may not cause G2 checkpoint defects due to this 
overlap in kinase response.   A second layer of redundancy also occurs with the 
ATR and ATM effector kinases, Chk1 and Chk2 respectively, as both kinases 
phosphorylate overlapping substrates in the G2 checkpoint.   
 The mec1-100 allele of the budding yeast ATR ortholog MEC1 dissociates 
S and G2 phase functions, suggesting ATR signaling in different cell cycle phases 
may have distinct requirements (207).   This allele contains the point mutations 
F1179S and N1700S, which correspond to L1405 and A1934 respectively in 
human ATR (207).   Neither amino acid is close to 3A-ATR residues in primary 
sequence, though I do not know their relative proximity in three-dimensional 
space.   Work by the Burgers group supports that there are distinct protein 
activators for Mec1 in G1, S, and G2 phases (103).   Dpb11 the yeast homolog of 
TopBP1 activates Mec1ATR in G2 while the Rad9 homolog Ddc1 functions in both 
G1 and G2 phases (103, 112, 113).   A double ddc1Δdpb11-1 mutant does not fully 
abolish S phase activation of Mec1, suggesting there is an undefined S phase 
activator of Mec1.   The 3A-ATR mutant is stimulated by TopBP1 and retains G2 
but not S phase functions.   Therefore it is possible that these mutations 
specifically disrupt regulation of ATR by an undefined protein activator in S 
phase.    
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A potential novel ATR regulatory region 
There is a dearth of structural information on ATR.   Structure function 
studies on ATR have also been difficult, as the ATR protein mislocalizes and is 
unstable when truncations or deletions are made.   This has made assigning 
functions to domains of the ATR protein difficult.   3A-ATR mutational analysis 
may have serendipitously uncovered a novel regulatory region in ATR that 
appears to also exist in other DNA damage response PIKKs.    
Cryo-EM and X-ray crystal structures of DNA-PK reveal a “crown” 
structure that consists of the FAT, kinase, and FATC domains (182, 218-220).   
The crown structure sits atop two “arms” consisting of the N-terminal HEAT 
repeats.   Juxtaposed between the crown and arm structures are irregular regions 
in the DNA-PK structure predicted to be flexible hinges.   Autophosphorylation 
produces a conformational shift in the DNA-PK structure possibly due to a shift 
in this flexible region.   Notably, the regulatory ABCDE DNA-PK 
autophosphorylation (T2609/S2612/T2638/T2647) cluster occurs just before the 
DNA-PK FAT domain (begins at aa2881) and may reside in this predicted 
flexible region.    
Indeed, by secondary structure prediction, the ABCDE cluster occurs 
between HEAT repeats in a 158aa inter-HEAT repeat loop (aa2566-2723) 
predicted to be unstructured except for a single short helix.   Examining HEAT 
repeat alignments by Perry and Kleckner (165), an analogous loop between 
HEAT repeat units occurs just before the ATR and ATM FAT domains.   ATM is 
autophosphorylated in the linker at S1893, and 3A-ATR residues occur in the 
region as well.   Furthermore, alignment of ATR and DNA-PK by secondary 
structure places ATR T1589 within 1-2 amino acids of DNA-PK 
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autophosphorylation sites T2609 and S2612.   These similarities among ATR, 
ATM, and DNA-PK suggest that the uncommonly long inter-HEAT repeat loops 
may be a shared regulatory region involved in controlling PIKK activity.    
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CHAPTER V 
 
FURTHER CHARACTERIZATION OF 16A-ATR MUTATIONS 
 
Introduction 
 It remains unclear if 3A-ATR residues are phospho-residues.  Secondary 
structure alignments suggest that the region containing these residues is 
regulatory in the related DNA damage kinases ATM and DNA-PK.  The 3A-ATR 
region is also present in ATR orthologues.  In this chapter, I briefly explore 
whether this region is also functional in S. cerevisiae Mec1ATR . 
16A-ATR mutations produce an interesting hyper-activation phenotype 
that does not segregate with 3A-ATR S phase defects.  Here I also define 6 
residues within 16A-ATR that cause to this phenotype.  These residues are 
distinct from 3A-ATR residues.  I also present preliminary evidence that hyper-
activation may be due to increased TopBP1 binding.   
 
Results 
 
Analysis of the 3A-ATR regulatory region in S. cerevisiae 
 While T1566, T1578, and T1589 are not conserved in S. cerevisiae, the 
extended inter-HEAT repeat loop is present in S. cerevisiae and other ATR 
orthologues.  Alignment of ATR orthologues by HEAT repeat units show that 
several residues within this region are highly conserved (Figure 35).  To 
determine if the functional importance of this region is conserved, I created three 
mutants, FRVF1349AAAA, E1354R, and W1359R, in the S. cerevisiae ATR  
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orthologue Mec1.  Because 3A-ATR exhibited replication stress response defects, 
I assayed the ability of these mutants to complement HU sensitivity in a 
mec1Δsml1Δ background.  Strains harboring an emptor vector exhibit HU 
sensitivity (Figure 36a).  WT-Mec1 rescues the HU sensitivity as does both the 
W1359R and E1354R mutants (Figure 36a).  In contrast, the FRVF1349AAAA 
mutant strain exhibits HU sensitivity comparable to vector only (Figure 36a).  In 
agreement with a defect in responding to replication stress, the FRVF1349AAAA 
mutant did not promote Rad53Chk1 phosphorylation after HU treatment (Figure 
36b).  However, Mec1 protein expression levels of the FRVF1349AAAA mutant 
were reduced compared to WT-Mec1 in several independent strains tested 
(Figure 36c).  Therefore, the inability to complement HU sensitivity may be due 
to lower levels of protein or improper protein folding.  When I expressed the 
mutant from a high copy 2µ plasmid, it was still unable to rescue HU sensitivity 
(Figure 36d).  This implies that protein levels may not be the cause of the defect; 
however, this experiment does not rule out the possibility of improper folding. 
 
Hyper-stimulation of ATR does not segregate with viability and S phase defects 
16A-ATR exhibits increased TopBP1-mediated activation in vitro.  I also 
observed this hyper-stimulation in the 12C-ATR mutant (Figure 37a) but not 
with the 3A-ATR mutant.   Instead a 6A-ATR mutant 
(S1333A/S1348A/T1376/S1782/T1890/S2143) with distinct mutations from 3A-
ATR is sufficient to augment TopBP1-mediated stimulation of ATR (Figure 37b).   
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Because ATR activation requires ATR binding to the AAD of TopBP1, I 
next examined whether hyper-stimulation is due to increased TopBP1 binding.  
GST-TopBP1-AAD interacted with HA-WT-ATR from stable WT-ATRdel/-TR and 
transiently expressed constructs in 293T cells (Figure 38).  Strikingly, 16A-ATR 
interaction with GST-TopBP1-AAD was increased (Figure 38).  This suggests that 
16A-ATR hyper-stimulation may be due to increased TopBP1 interaction. 
It is not clear what functional consequences hyper-stimulation may have 
in cells.  16A-ATRdel/-TR cell lines exhibit increased basal Chk1 phosphorylation 
(Figure 23b), but 3A-ATR cells do not (Figure 28a).  Preliminary results in 6A-
ATRdel/-TR cell lines also show increased Chk1 phosphorylation in the absence of 
damage (Figure 39a).  In contrast phosphorylated RPA is not increased in 6A cell 
lines, suggesting that the increase in Chk1 phosphorylation is not due to DNA 
damage.  While more experiments are required, the increase in Chk1 
phosphorylation also does not correlate well with ATR protein levels (Figure 
39b).  This supports that hyper-activation also occurs in cells.  Whether this 
increase in Chk1 phosphorylation amounts to other functional consequences 
remains unclear.  Additional 6A-ATRflox/-TR cell lines with similar expression to 
WT cells are required for this analysis.   
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Discussion 
There are few defined regulatory regions in ATR, and structural 
information of ATR is lacking.  Because of this, the inter-HEAT repeat loop 
where 3A-ATR mutations reside is an interesting region for future ATR studies 
especially since it is conserved among ATR orthologues and also occurs in ATM 
and DNA-PK.  I was unsuccessful in determining whether 3A-ATR residues are 
phosphorylated.  It is a good possibility that the mutations disrupt other forms of 
regulation, which the yeast FRVF-AAAA mutant data supports.  It would be 
interesting to conduct a systematic analysis of the conserved residues in this 
region in yeast.  Identifying other functional residues that do not disrupt protein 
levels when mutated would help future study of the region.  Alternatively, 
confirming that the FRVF-AAAA mutant has normal basal kinase activity would 
alleviate protein folding issues.  If other mutations that do not disrupt protein 
levels were identified, an overexpression suppressor screen could be conducted 
to identify proteins that function through this region.   
To my knowledge, 6A-ATR mutations are the first mutations that produce 
a super-activatable ATR kinase.  6A-ATR mutations do not create a constitutively 
activated ATR kinase.  Instead the mutations substantially potentiate TopBP1-
mediated stimulation of kinase activity.  This suggests there are additional 
regulatory steps in TopBP1-mediated activation of ATR mediated by 6A-ATR 
mutations.  Three of the 6A-ATR mutations occur in the ATR FAT domain.  
Rapamycin binds mTOR in its FAT domain to inhibit mTOR activity (221).  The 
model of ATM activation suggests that the FAT domain occludes the kinase 
domain in inactive dimers and autophosphorylation within the FAT domain 
relieves this inhibition by transitioning to a monomer state (162).  It is possible 
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that the FAT domain of ATR also serves as a negative regulatory input whether 
through binding of an inhibitory protein, inhibitory post-translational 
modification, or auto-inhibitory interactions that are relieved allosterically upon 
kinase activation.   
There are many tantalizing possibilities that could explain hyper-
activation.  ATR signaling to Chk1 in cells requires protein phosphatase 5 (PP5), 
and PP5 and ATR co-immunoprecipitate, suggesting that dephosphorylation of 
ATR contributes to ATR activation (222).  One attractive hypothesis is that 6A-
ATR residues are inhibitory phosphorylation sites.  I have no evidence that 6A-
ATR perturbs ATR phosphorylation.  However, several alternative experiments 
to test this hypothesis are feasible.  For instance, PP5 silencing perturbs ATR-
dependent Chk1 phosphorylation in cells.  6A-ATR expressing cells should be 
refractory to PP5-deficiency if 6A-ATR residues are dephosphorylated by PP5.  
In addition, phosphatase treatment of WT-ATR but not 6A-ATR should increase 
TopBP1 interaction in GST-pulldown assays.  However, one consideration is that 
damaging cells prior to in vitro stimulation of ATR does not increase ATR 
activation (unpublished D.M.), possibly due to not preserving ATR 
phosphorylation during purification.  Comparison of phospho-mimetic mutants 
may be a better approach.   
My preliminary data shows that TopBP1 binding is increased with 16A-
ATR.   Hyper-activation may be due to an artifact, perhaps by creating an 
artificial TopBP1 binding surface on the mutant ATR protein or a “sticky” ATR.  
Defining the minimal mutations that produce hyper-activation will alleviate 
some of these concerns.  Interestingly, screens for activating mutations in yeast 
TOR identified many activating mutations in the TOR FAT domain that 
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conferred growth in the absence of the TOR activator Rheb or in the presence of 
the nonspecific mTOR inhibitor caffeine (223, 224).  Therefore it is possible that 
TopBP1 binding may also be regulated by residues in the FAT domain.   
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CHAPTER VI 
 
CHARACTERIZATION OF A NOVEL ATR KINASE INHIBITOR 
 
Introduction 
Ectopic oncogene expression both in cultured human cells and in 
xenograft models drives aberrant proliferation and leads to activation of the 
ATR-Chk1 pathway.  Work at the single DNA fiber level suggests activation of 
ATR is due to DNA replication stress.  ATR also is activated in neoplasias but not 
in adjacent normal tissue, and this activation is associated with cell cycle arrest, 
exit, or cell death. This suggests that ATR signaling may constitute a barrier to 
cancer (72-74, 225).  Bypass of this barrier may be a double-edged sword for the 
cancer cell, as they may exhibit an increased dependency on the ATR pathway, 
analogous to oncogene addiction, to continue to replicate in the presence of 
oncogene-induced replication stress.  ATR inhibition may be efficacious in these 
types of tumors.  Furthermore, many current therapies are DNA damaging 
agents that increase the signaling burden on the ATR pathway, and ATR 
inhibition may increase their therapeutic index.  In addition to these important 
clinical applications, a selective ATR inhibitor would also greatly advance basic 
research.  Temporal studies of ATR function, which are difficult in genetic 
systems, would be possible.   
I received a novel proprietary ATR inhibitor from AstraZeneca designated 
AZ20.  While AZ has not disclosed the chemical structure of AZ20, it is an ATP 
analog.  As a basic research tool, I used AZ20 to transiently inhibit ATR kinase 
activity during specific cell cycle phases and observed that ATR inhibition 
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perturbs DNA replication as expected from genetic studies.  I also determined 
that ATR activity is required during prolonged replication fork stalling and 
during the recovery phase of DNA replication after replication stress.  Finally, I 
began preliminary studies to examine the effectiveness of AZ20 as a single agent 
and found that AZ20 alone is cytostatic, likely due to off-target inhibition of 
mTOR.  Instead, AZ20 sensitized cells to the replication stress agent HU, and 
ATM-deficiency sensitized cells to AZ20 treatment.   
 
Results 
 
Characterization of AZ20-mediated ATR inhibition 
I examined ATR-dependent Chk1 phosphorylation after HU treatment in 
U2OS cells to determine whether AZ20 inhibits ATR activity in cells.  Chk1 
phosphorylation increased after 4 hours of HU treatment (Figure 40a, Lane 1 vs 
2).  Simultaneous addition of AZ20 and HU inhibited Chk1 phosphorylation 
beginning at 1 µM with maximum inhibition occurring at 10µM (Figure 40a).  
Even at 10µM AZ20, inhibition of Chk1 phosphorylation was not complete.   
I also determined the reversibility of ATR inhibition by co-treating cells 
with HU and 10µM AZ20 for 4 hours and then chasing into HU alone.  At least 
by 2 hours of AZ20 removal, ATR inhibition is reversed and Chk1 
phosphorylation levels increased (Figure 40a, lane 7 vs. 8).  The reversal of 
inhibition is likely to occur much faster, but I did not analyze shorter chase times.  
Nonetheless, the reversibility of the inhibitor allows for transient inhibition of 
ATR. 
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AZ20 inhibits ATR but not ATM 
 ATR and ATM are closely related DNA damage PIKK kinases with the 
highest degree of similarity occurring in the C-terminal kinase domain.  AZ 
initially determined AZ20 to be 10-fold more selective for ATR versus ATM or 
mTOR in an in vitro kinase activity screen (personal communication).  To confirm 
ATR selectively in cells, I examined whether AZ20 inhibited ATM-dependent 
Chk2 phosphorylation.  ATM phosphorylated Chk2 after ionizing radiation (IR) 
in U2OS cells (Figure 40b, lane 1 vs. 4), and AZ20 treatment had no effect on this 
phosphorylation (Figure 40b, lane 4 vs. 5).  In contrast AZ20 inhibited Chk2 
phosphorylation after ultraviolet (UV) treatment (Figure 40b, lane 2 vs. 3), which 
is in agreement with previously published findings that Chk2 phosphorylation 
after UV is ATR-dependent.  Therefore AZ20 specifically inhibits ATR and not 
ATM.   
 
AZ20 inhibits ATR rapidly 
 To determine how quickly AZ20 inhibits ATR in cells, I treated U2OS cells 
with HU for 4 hours and then chased cells into HU alone or HU and AZ20 for the 
indicated times.  Chk1 phosphorylation remained increased when HU treated 
cells were chased into HU (Figure 40c, lanes 2-6).  In contrast, Chk1 
phosphorylation decreased within 30 minutes of chasing into HU and AZ20 
(Figure 40c, lane 3 vs. 7). 
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AZ20 perturbs DNA replication 
 ATR functions in S phase to promote completion of DNA replication 
through regulating replication origin firing and replication fork progression, 
stability, and restart.  To analyze AZ20 effects on cell cycle progression in a 
synchronous population of cells, I utilized hTERT immortalized RPE cells, which 
undergo contact inhibition and reversible G0/G1 arrest (Figure 41a).  I confirmed 
exit from the cell cycle by BrdU pulsing contact inhibited cells for 15 minutes 
prior to sample collection.  The majority of contact inhibited cells contained 2N 
DNA content with very few BrdU positive cells (Figure 41b, 0 hour).  Contact 
inhibited RPE cells re-enter the cell cycle when contact inhibition is relieved by 
passaging cells to non-confluent conditions.  The burst in BrdU positive cells at 
16 hours demonstrates this cell cycle re-entry, and cells progress through the cell 
cycle to 4N DNA content at 24 and 36 hours (Figure 41b, Top).  Release of contact 
inhibited cells into AZ20 delayed the initial burst of BrdU incorporation by at 
least 8 hours and overall cell cycle progression, since by 36 hours there are also 
very few 4N DNA content cells (Figure 41b).  At 36 hours AZ20 depressed BrdU 
incorporation.  Strikingly, a distinct population of these BrdU positive cells 
exhibited grossly reduced incorporation further suggesting a disturbance in 
replication (Figure 41b, bottom 36h).  These results are consistent with previously 
published genetic experiments. 
 In the previous experiment, AZ20 is present continuously after release 
from contact inhibition.  Much like genetic manipulations of ATR, this makes it 
impossible to discern the effect of the drug on specifically S phase cells.  To 
examine the effects of AZ20 specifically on cells in S phase, I released cells from 
contact inhibition into media only for 12 hours, which is prior to initial BrdU  
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incorporation (Figure 41b).  After 12 hours of release into media, cells were 
chased into DMSO control or AZ20 (Figure 42a).  Control cells progressed 
through S phase (Figure 42b, top) with BrdU positive cells at every time point 
and the appearance of 4N DNA content by 24 hours. 
Cells chased into AZ20 exhibited a 4 hour delay in initial BrdU 
incorporation, which is not as pronounced as when cells were continuously 
released into AZ20.  This suggests that AZ20 treatment in G0/G1 may contribute 
to the delay (addressed below).  At 20 hours, AZ20 chased cells incorporated 
BrdU to a similar extent as control cells at 16 hours.  However by 24 hours AZ20 
chased cells exhibit depressed BrdU incorporation, consistent with results in 
Figure 41b (Figure 42b, bottom).  Note, the difference in timing of the depressed 
BrdU incorporation (36 hour in Figure 41 and 24 hour in Figure 42) is likely due 
to the difference in delay of initial BrdU incorporation.  Overall the data supports 
that AZ20 treatment in S phase perturbs DNA replication.   
 
AZ20 disrupts recovery from replication stress 
 In addition to functioning during unperturbed replication, ATR 
genetically has been shown to be required for recovery of DNA replication 
following replication stress (18, 35).  To assess whether AZ20 disrupts recovery 
of DNA synthesis after replication stress, I stalled replication forks in U2OS cells 
with 16 hours of HU treatment.  This arrests cells in early S phase (Figure 43, 0 
hour).  I removed the HU and then released cells into DMSO control or AZ20 and 
nocodazole to prevent cells from exiting mitosis.  DNA content analysis shows 
that control cells progress from 2N to 4N DNA by 10 hours after release from HU 
(Figure 43, black histograms).  Cells released into AZ20 for 4 hours and 6 hours  
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do not appear to have significant problems.  However at 8 hours, cells released 
into AZ20 begin to accumulate in S phase (Figure 43, clear histogram).  These 
cells do not progress to 4N DNA content even after 16 hours of release into 
AZ20.  This data supports that AZ20 perturbs recovery from replication stress. 
 The function of ATR during prolonged replication fork stalling is not 
easily separable from DNA completion during recovery with genetics.  To assess 
ATR function during a prolonged replication stall, I stalled replication forks with 
HU for 16 hours and then continued to stall forks either in HU and DMSO 
control or in HU and AZ20 for an additional 24 hours.  Cells were then released 
into nocodazole, and DNA content was analyzed (Figure 44a).  Cells stalled in 
the presence of HU and DMSO could resume DNA synthesis and a large 
percentage completed synthesis with 4N DNA content (Figure 44b, black 
histograms), although some cell death occurred likely due to the prolonged 
arrest.  Strikingly, very few cells arrested in HU and AZ20 reached 4N DNA 
content when released (Figure 44b, clear histogram).  In addition to cell death, a 
large percentage of AZ20 treated cells remain arrested.   This data implies that 
ATR activity is also important during prolonged fork stalling possibly to prevent 
replication fork collapse and to prevent origins from firing. 
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AZ20 delays entry into S phase 
 In initial RPE release experiments, I observed a substantial delay in S 
phase entry when I released contact inhibited cells directly into AZ20 (Figure 
41b). This effect was not as large when I treated cells with AZ20 only in S phase 
(Figure 42b), suggesting that ATR inhibition during G0/G1 contributes to the 
delay.  To test this hypothesis, I released contact inhibited RPE cells immediately 
into DMSO control or AZ20 for 8 hours, chased cells into media, and BrdU 
pulsed cells 30 minutes prior to sample collection (Figure 45a).  I chose the 8 hour 
treatment time, since released cells do not incorporate BrdU until 12-16 hours 
after release.   Furthermore, from earlier characterization I determined that ATR 
inhibition was reversed within 2 hours of a chase.   20 hours after release, more 
than 50% of cells treated with DMSO during the initial 8 hours of release 
incorporated BrdU (Figure 45b and c).  In contrast 25% of cells treated with AZ20 
during the first 8 hours of release incorporated BrdU at 20 hours (Figure 45b and 
c).  By 24 hours AZ20 treated cells reached percentages of BrdU positive cells 
observed in control cells at 20 hours.  However, AZ20 treated cells did not exhibit 
a problem in replicating once they entered S phase, since they incorporated BrdU 
at similar intensities (data not shown).  These results suggest that AZ20 
treatment during G0 and G1 delays entry into S phase.   
 While I have shown that cells released from contact inhibition do not 
incorporate BrdU until some time between 12 and 16 hours, I wanted to rule out 
the possibility that AZ20 was being added during early time points of replication 
origin firing not discernable by BrdU incorporation.  To do this, I treated cells 
released from contact inhibition for 4 hours at different windows during the first 
12 hours of release (ie. 0-4hrs, 4-8hrs, and 8-12h; Figure 46a) and then chased into  
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media.  Treating cells with AZ20 during the first four hours of release did not 
cause cells to delay BrdU incorporation (Figure 46b, 0-4 hour).  Released contact 
inhibited cells are most likely progressing from G0 to G1 during this time.  In 
contrast, releasing cells into media for the first four hours, then treating them 
with AZ20 for hours 4-8, and then releasing them into media caused a delay in S 
phase (Figure 46b).  Similarly, releasing cells for the first 8 hours and then 
treating them with AZ20 from hours 8-12 and then releasing them into media 
also caused a delay in S phase (Figure 46b).  These results indicate that a short 
treatment of four hours in G1 is sufficient to delay entry into S phase.  Moreover 
treatment during hours 4-8 suggest that this delay is not due to inhibition of S 
phase cells that have fired origins but not incorporated significant amounts of 
BrdU. 
I confirmed that the delay of entry into S phase was not specific to the RPE 
cell type.  AZ20 treatment of primary human fibroblasts released from contact 
inhibition also delayed S phase entry (data not shown).  The S phase delay is also 
not specific to the type of synchronization.  In asynchronous U2OS cells, I BrdU 
pulsed cells at the start of the experiment to distinguish G1 (2N, BrdU negative) 
and S phase (BrdU positive cells) cells and then added AZ20 and nocodazole for 
the indicated times (Figure 47a).  BrdU positive cells treated with DMSO control 
completed DNA synthesis by 12 hours (Figure 47b).  The majority of BrdU 
positive cells treated with AZ20 also completed S phase but a portion of these 
cells also remained in S phase.  This confirms RPE experiments showing that 
AZ20 treatment of S phase cells perturbs replication.   
When examining the BrdU negative population, control cells progressed 
from 2N to 4N DNA content by 24 hours (Figure 47b).  However, BrdU negative  
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AZ20 treated cells progressed from 2N to 4N DNA content at much slower rates 
than control cells, and a significant amount remained in G1 and early S phase 
(Figure 47b).  This confirms that treating G1 cells slows entry into S phase.  
Additionally, any effect from AZ20 treatment of mitotic cells is unlikely to be 
visible in these experiments since I added nocodazole to the media. 
 
AZ20 delays RB phosphorylation  
No known function for ATR in G1 has been reported.  One possibility is 
that ATR inhibition in G1 may cause DNA damage and enact a G1 checkpoint.  
Since ATM is the major kinase response for eliciting the G1 DNA damage 
checkpoint, I next examined whether ATM activity contributed to the G1 effects 
observed.  Prolonged treatment of ATR in asynchronous U2OS causes cells to 
accumulate with 2N DNA content, which is indicative of the G1 delay.  Co-
administration of ATR and ATM inhibitors did not alleviate this accumulation, 
suggesting that the accumulation is not due to a G1 DNA damage checkpoint 
(Figure 48a).   
 I next examined whether AZ20 inhibited cyclin-dependent kinase (CDK) 
activity.   In G1, Cyclin D-CDK4/6 phosphorylates the Retinoblastoma protein 
(RB), which relieves inhibition of the transcription factor E2F to promote 
transcription of genes required for S phase.  I examined RB phosphorylation in 
RPE cells released from contact inhibition and observed an increase in RB 
phosphorylation at 12 hours (Figure 48b).  AZ20 treatment transiently during the 
first 8 hours of release from contact inhibition caused a delay in RB 
phosphorylation (Figure 48b).  This suggests that AZ20 delays entry into S phase 
by delaying RB phosphorylation in G1.    
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There is very little evidence for ATR-mediated promotion of Cyclin D-
CDK4/6 activity.  It is possible that AZ20 non-selectively inhibits CDK4/6.  
However, an ATR-related PIKK kinase, mTOR, regulates growth control, protein 
synthesis, and G1 progression in response to mitogenic signals (221).  mTOR 
inhibition perturbs cyclin D accumulation in G1 cells (226, 227).  Therefore I 
tested whether AZ20 G1 effects are off-target and due to mTOR inhibition.  To 
examine mTOR inhibition, I examined phosphorylation of the S6 ribosomal 
protein subunit.  S6 phosphorylation is visible 8 hours after release from contact 
inhibition in control RPE cells (Figure 48c).  In cells treated transiently with AZ20 
for the first 8 hours after release, S6 phosphorylation is delayed and does not 
appear until 12 hours (Figure 48c).  I also confirmed mTOR inhibition in U2OS 
cells.  Addition of serum to serum-starved U2OS cells induced S6 
phosphorylation (Figure 48d).  AZ20 treatment inhibited serum-induced S6 
phosphorylation almost as potently as the mTOR inhibitor rapamycin (Figure 
48d).  From this data, I conclude that AZ20 is not ATR selective but also targets 
mTOR. 
 AZ20 inhibition of mTOR suggests that the delay in S phase entry is due 
to mTOR inhibition.  In an attempt to distinguish whether ATR or mTOR 
inhibition is contributing to this phenotype, I first determined that the minimal 
concentration of AZ20 that causes the S phase delay is 500nM (Figure 49a).  I 
then assayed for the concentration of AZ20 at which mTOR inhibition begins.  
Inhibition of mTOR-dependent S6 phosphorylation also begins at 500nM (Figure 
49b).  Furthermore, ATR-dependent Chk1 inhibition does not occur until 1µM 
(Figure 40a).  Together, ATR and mTOR inhibition by AZ20 occur at similar 
ranges of drug concentration.  This precludes me from determining the  
 140 
 
 
 
 141 
contribution of ATR and mTOR inhibition in G1 cells, although only mTOR of 
the two has well established roles in G1.  Of note, S phase defects caused by 
AZ20 are not likely to be due to mTOR inhibition, as mTOR regulation of DNA 
replication has not been shown. 
 
Replication stress potentiates AZ20 cytotoxic effects  
 Despite the non-selectively of AZ20, the drug did perturb replication and 
recovery from replication stress in S phase cells.  Therefore, I assessed the 
cytotoxic affects of AZ20 treatment in U2OS cells.  Static treatment of AZ20 alone 
caused very little cell death within 24 hours of treatment, since most cells 
accumulated in G1 and early S phase.  Even after 72 hours of AZ20 treatment, 
only 21.4% of cells had sub-G0/G1 DNA content while most cells remained in G1 
or S (Figure 50a).  However, when cells are simultaneously treated with AZ20 
and HU, 26.8% of cells died and by 72 hours 41.8% of cells underwent cell death 
(Figure 50a).  HU alone at 72 hours only caused 28.3% cell death.  This data 
suggests that AZ20 alone is cytostatic, likely because of mTOR inhibition slowing 
cells from entering S phase.  However, replication stress enhanced cell killing by 
AZ20 compared to AZ20 or HU alone.   
 The above results suggest that increasing the replication stress burden of 
the cell increases the therapeutic index of AZ20.  To further test this hypothesis, I 
arrested cells in HU and then released cells continuously into AZ20 or AZ20 and 
HU for 24, 48, and 72 hours.  In each case, I also released cells into the treatments 
for only 24 hours and assessed cell death at 24, 48, and 72 hours.  Cells released 
into DMSO control exhibited only 9.2% cell death at 72 hours.  In contrast, release 
of cells into AZ20 caused 17.4%, 30.8%, and 57.6% cell death at 24, 48, and 72  
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hours respectively (Figure 50b).  Only 24 hours of exposure to AZ20 after the 
release was sufficient to cause substantial cell death at 48 and 72 hours with 33% 
and 41.5% cell death respectively (Figure 50b).  Release of cells into AZ20 and 
HU continuously caused 16.1%, 51.7%, and 53.1% cell death at 24, 48, and 72 
hours.  Release for only 24 hours into AZ20 and HU resulted in 32.7% and 36.6% 
cell death at 48 and 72 hours again showing that cell death increases even after 
just 24 hours of AZ20 treatment (Figure 50b).   These data indicate that 
replication stress increases the therapeutic index of AZ20 and that the 
therapeutic window is in S phase cells. 
 
ATM deficiency increases AZ20 sensitivity 
 Understanding the genetic determinants of AZ20 sensitivity is important 
in order to individualize therapy.  I began some preliminary studies to assess 
whether p53 and ATM status affect AZ20 sensitivity.  I assessed whether p53 
deficiency could sensitize cells to AZ20 using an isogenic pair of HCT116 colon 
carcinoma p53+/+ and p53-/- cell lines.  The IC50 of AZ20 in p53+/+ cells was 
0.36µM and 0.15µM in p53-/- cells (Figure 51a).  Thus, p53 status does not 
significantly sensitize cells to AZ20.  In contrast to p53, ATM deficiency 
significantly sensitized cells to AZ20.  Human fibroblasts isolated from an Ataxia 
Telangiectasia-Mutated patient integrated with a WT-ATM vector had an IC50 
concentration of 0.7µM. ATM-deficient cells integrated with vector only were 
seven-fold more sensitive to AZ20 with an IC50 value of 0.1µM (Figure 51b).  
Sporadic Lymphomas and breast cancers exhibit high incidence of loss of ATM 
function and could be good candidates for ATR inhibition (23, 228).   
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Discussion 
In this chapter I characterize a novel ATR inhibitor, AZ20, and use it to 
examine the temporal requirements of ATR in the response to replication stress.  
ATR activity is required both when replication forks are stalled and also during 
DNA replication after fork stalling agents are removed.  Hydroxyurea 
potentiated AZ20-mediated cytotoxicity in U2OS cells.  AZ20, while selective for 
ATR and not ATM, also inhibits the related PIKK mTOR.  mTOR inhibition 
causes a G1 delay and delays entry into S phase where ATR inhibition would be 
most efficacious.  Finally while p53-deficiency mildly sensitized cells to AZ20, 
ATM-deficiency sensitized cells to AZ20 seven-fold.   
 
Temporal requirements for ATR activity after replication stress 
 In S. cerevisiae, experiments using inducible expression of Rad53Chk1 show 
that loss of Rad53 function during fork stalling cannot be rescued by re-
expression of Rad53 after fork stalling agents are removed due to irreversible 
fork collapse (142).  Similarly using the ATR inhibitor, I find that transiently 
inhibiting ATR activity once replication forks are stalled greatly perturbs 
completion of replication when fork stalling agents and AZ20 are removed.  This 
suggests that in mammalian cells ATR activity is also required for fork stability.  
Direct analysis of replication forks by DNA fiber labeling will be necessary to test 
this hypothesis.  In addition, RAD53 null defects can be rescued by deletion of 
the nuclease Exo1 while MEC1 deficiency cannot (143).  It would be interesting to 
compare Chk1 inhibition to ATR inhibition in mammalian cells and to also test 
whether nuclease inhibition can rescue these defects.   
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My data also supports that ATR activity is required during DNA 
replication after fork stalling agents are removed.  One interesting observation in 
these experiments is differences in DNA content are not observed until 6 hours 
after inhibition of ATR in cells following release from replication stress.  This is 
not due to the kinetics of ATR inhibition, as inhibition in cells occurs within 30 
minutes.  I also pre-treated cells for 1 hour prior to release and obtained similar 
results (not shown).  This raises the question of what the function of ATR is 
during the recovery phase and where this early DNA synthesis is coming from.  
Is the DNA synthesis from restarted forks that lose stability in the absence of 
ATR activity?  Alternatively, is there aberrant origin firing due to loss of ATR 
activity?  Again DNA fiber labeling is required to examine the state of replication 
forks and origin firing.  In addition to fiber labeling, purification of replication 
forks via the isolation of nascent DNA by iPOND under temporal inhibition of 
ATR activity will identify proteins that are involved in regulating replication fork 
stability, which are largely unknown (229).   
 
Clinical implication of AZ20 
 Many studies have shown that activated oncogenes cause replication 
stress and activation of the ATR pathway in tumors (73, 74).  Because ATR is an 
essential gene and is required to respond to replication stress, it is thought that 
inhibition of ATR signaling in tumors would be cytotoxic.  I found that AZ20-
mediated cytotoxicity was potentiated by replication stress in U2OS supporting 
this hypothesis.  Another study using a different ATR inhibitor also showed 
increased DNA damage with overexpression of the oncogene cyclin E and ATR 
inhibition compared to vector expressing cells (205, 206).  An important future 
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direction will be to test this hypothesis comprehensively in xenograft models 
using activated oncogenes and to explore the use of ATR inhibitors in 
combination with therapeutics that cause replication stress.    In addition I found 
that ATR inhibition for only 24 hours was sufficient to cause significant cell death 
after an initial treatment of replication stress.  This implies that scheduling of 
ATR inhibition in patients may be best after a replication stress agent such as 
cisplatin and only be required for a short period of time.  Testing different 
treatment regimens will be important to minimize side-effects from ATR 
inhibition in rapidly proliferating non-malignant cells.  Additionally, large scale 
screenings of tumor-derived cell lines may show a correlation between the 
efficacy of ATR inhibition and the state of replication stress in the cell line.   
 ATM-deficiency also potentiated AZ20-mediated cytotoxicity.  This is 
likely due to the generation of double-strand breaks in the absence of ATR 
activity.  ATM would normally respond to these double-strand breaks to mediate 
cell cycle checkpoints and DSB break repair.  Loss of ATM and ATR could lead to 
the accumulation of DNA DSBs and cell death.  This result predicts that tumor 
types that often exhibit inactivation ATM, such as lymphomas and sporadic 
breast cancers, would be sensitive to ATR inhibition (23, 228).  Additionally, 
genome wide RNAi screens would be an important future direction to identify 
potential genetic backgrounds that would be sensitive to ATR inhibition.   
 
mTOR inhibition 
AZ20 treatment also causes mTOR inhibition and a G1 delay.  Prolonged 
treatment of AZ20 alone caused cells to accumulate in G1 and entry into S phase 
is greatly delayed.  AZ20 treatment alone did not substantially increase cell 
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death, likely due to preventing cells from entering S phase where ATR inhibition 
would be most efficacious.  Synchronization of cells in early S phase with the 
replication stress agent hydroxyurea greatly sensitized cells to AZ20.  This is 
probably due to both increased replication stress and synchronization of cells in 
S phase.  Future derivatives of AZ20 and other available ATR inhibitors should 
be examined for mTOR inhibition, as mTOR inhibition may be 
counterproductive to ATR inhibition.   
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CHAPTER VII 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 The hypothesis that phosphorylation regulates ATR at first glance is 
seemingly simple.  However, definitively answering this question has been 
exceedingly difficult.  My research constitutes one of the first concentrated efforts 
in studying phospho-regulation of ATR.   
 
ATR T1989 phosphorylation marks an active kinase 
 Prior to my research it was unknown whether ATR was phosphorylated 
in response to DNA damage.  In Chapter III, I identify and characterize the first 
DNA damage-regulated ATR phosphorylation site.  DNA damage induces 
phosphorylation on ATR T1989.  Ablation of T1989 phosphorylation causes a 
partial viability defect, but the function of this phosphorylation remains unclear.  
T1989 phosphorylation occurs concurrently with ATR-dependent Chk1 
phosphorylation and requires ATR kinase activity and activation via the PIKK 
Regulatory Domain in cells. This supports that T1989 phosphorylation occurs on 
an activated ATR kinase.  Monitoring T1989 phosphorylation with a phospho-
peptide specific antibody can serve as a direct marker for ATR activity.  This is a 
major advancement for studying ATR signaling.   
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S and G2 functions of ATR are separable 
 I test the hypothesis that candidate autophosphorylation sites regulate 
ATR activity in Chapter IV and uncover mutations that dissociate the S and G2 
functions of ATR.  Mutation of three candidate ATR autophosphorylation sites 
creates a 3A-ATR (T1566A/T1578A/T1578A) mutant protein that cannot 
complement cell viability and S phase defects due to ATR deletion.  However, 
the G2 checkpoint remains intact in 3A-ATR expressing cells.  3A-ATR viability 
defects correlate with reduced ATR-dependent Chk1 phosphorylation and 
perturbed completion of DNA synthesis after replication stress.  Thus, 3A-ATR 
mutations are the first identified and characterized mutations in human ATR that 
dissociate S and G2 phase activities.    
3A-ATR experiments demonstrate that the G2 checkpoint activity of ATR 
is dispensable for the essential function of ATR to promote cell viability.  The 
correlation between viability and replication stress response defects in 3A-ATR 
expressing cells suggest that the essential function of ATR in human cells is to 
respond to DNA replication stress in S phase.  However, the function of 3A-ATR 
residues remains unknown.   
 
Identification of a novel regulatory region 
 3A-ATR residues occur in a distinct inter-HEAT repeat loop adjacent to 
the ATR FAT domain.  An analogous region also is present in ATM and DNA-
PK and is targeted for critical autophosphorylation in these kinases.  While I 
cannot conclude 3A-ATR residues are phosphorylated, my data suggests that the 
region is also important for ATR function.  I also provide preliminary evidence 
supporting that the regulatory region is conserved in budding yeast.   
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Additional regulatory steps exist in TopBP1-mediate activation of ATR 
 16A-ATR is hyper-stimulated by the ATR Activation Domain (AAD) of 
TopBP1 in vitro.  This is the first report of a hyper-stimulatable ATR kinase.  I 
localize the responsible mutations to 6 candidate autophosphorylation sites that 
are distinct from the 3A-ATR mutant residues.  Preliminary experiments also 
indicate that the hyper-stimulation of the ATR mutants is due to increased 
binding with the TopBP1 AAD.  While the mechanism of hyper-stimulation is 
unclear, these data reveal that there may be additional regulatory steps in 
TopBP1-mediated activation of ATR.   
 
ATR kinase activity is important during replication fork stalling and completion of 
replication following fork stalling 
 
 Genetic studies demonstrate that ATR is critical to respond to replication 
stress.  These studies imply that ATR functions to stabilize stalled replication 
forks, regulate origin firing, and restart collapsed replication forks.  Yet 
temporally it is unclear from genetic manipulation whether ATR activity is 
required during replication fork stalling, during replication recovery, or at both 
stages.  In Chapter VI, I use a novel ATR inhibitor and discover that ATR is 
required under both conditions.  However, the function of ATR during these 
stages of the replication stress response remains to be determined. 
 
Determinants of ATR inhibition sensitivity 
 ATR inhibition with AZ20 increases cell death.  However, release of cells 
from HU arrest into AZ20 causes a 5-fold increase in cell death compared to cells 
treated with HU alone.  This suggests that the therapeutic index of ATR 
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inhibitors can be augmented with replication stress agents or in tumors with 
high levels of replication stress.   
 Genetically, ATM and p53 deficiency sensitize cells to ATR inhibition.  p53 
deficiency causes a 2-fold decrease in cell viability while ATM deficiency 
sensitizes cells to ATR inhibition 7-fold.  This suggests that tumors with ATM 
mutations, such as sporadic breast and lymphomas, may be good candidates for 
therapies inhibiting ATR.  Genome-wide screens for other genetic determinants 
of sensitivity to ATR inhibition will be an important future step.   
 AZ20 also inhibits the related PIKK mTOR.  AZ20-mediated inhibition 
causes cells to accumulate in G1 and delays entry into S phase. This G1 
accumulation is counterproductive for the cytotoxic effects of ATR inhibition, 
which is potentiated by DNA replication stress.  As a consequence, AZ20 as a 
single agent was not very effective and future derivatives of ATR inhibitors 
should aim to not target mTOR.   
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Future Directions 
 
ATR activation 
 Activation of the ATR kinase requires independent localization of the 
ATR-ATRIP complex and ATR signaling factors to Replication Protein A-coated 
single-stranded DNA (RPA-ssDNA) (18).  RPA-ssDNA can be considered 
analogous to a signaling scaffold to concentrate ATR signaling factors when 
there is DNA damage (Figure 52a).  ATR-ATRIP recruitment to RPA-ssDNA 
occurs through an interaction between ATRIP and the 70kDa subunit of RPA 
(Figure 52b) (84, 87).  Independent of ATR-ATRIP recruitment, the Rad17-RFC 
clamp loader loads the Rad9-Rad1-Hus1 (9-1-1) complex to a 5’ recessed junction, 
perhaps due to the interaction of Rad9 with the 70N domain of RPA (Figure 52b) 
(93-95).  9-1-1 recruitment facilitates localization of the ATR activator TopBP1.  
This proceeds through an interaction between TopBP1 BRCT repeats and the 
phosphorylated tail of Rad9 (230).  TopBP1 interacts directly with the ATR PRD 
and a region on ATRIP (Figure 52c) (90).  TopBP1 binding of ATR PRD 
presumably causes a conformational shift that increases ATR substrate affinity 
(110).  Once activated, ATR phosphorylates substrates like Chk1 and 
concurrently ATR T1989 becomes phosphorylated in an ATR-dependent manner 
(Figure 52d) (191).  
 
Recruitment of ATR-ATRIP and ATR signaling factors  
 Recent work demonstrates that artificial tethering of TopBP1-LacR to 
integrated Lac-O sequences in the absence of DNA damage is sufficient to 
activate ATR as measured by phosphorylation of the ATR substrate Chk1 (105).   
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Other groups report similar results in yeast (104), and similar experiments 
tethering the ATM activator complex MRN demonstrate that concentration of 
MRN is sufficient to activate ATM (231). These data emphasize that 
concentrating the ATR kinase with its activator TopBP1 is sufficient for signaling. 
 While I have described a step-wise linear mode of ATR-ATRIP and 
TopBP1 recruitment to RPA-ssDNA, data in the field suggests that there are 
other modes of recruitment for both ATR-ATRIP and TopBP1 to RPA-ssDNA.  In 
addition, localization may not be limited to the RPA-ssDNA scaffold.  
 An acidic checkpoint recruitment domain of ATRIP interacts with a basic 
cleft in the 70kDa subunit of RPA (87).  Mutation of either of these domains 
prevents ATR-ATRIP binding to RPA-ssDNA with minimal consequences to 
checkpoint signaling (84). This supports that there may be alternative modes of 
ATR-ATRIP recruitment.  For instance in both yeast and mammalian cells, Cdc6 
interacts with ATRIP. Cdc6-deficiency perturbs ATR-ATRIP chromatin 
association and checkpoint signaling (232, 233).  Whether this Cdc6-dependent 
chromatin association depends on RPA-ssDNA is not clear (Figure 53a).  
Perhaps more intriguing than protein factors that may be semi-redundant 
or cooperative with RPA-ssDNA are RPA-ssDNA-independent mechanisms.  
ATR-dependent Chk1 phosphorylation in response to base alkylation in cells 
requires mismatch repair (MMR) proteins.  In contrast, RPA-ssDNA generating 
agents such as HU do not depend on MMR proteins for ATR signaling (234).  
While processing alkylated bases may lead to RPA-ssDNA, evidence supports 
that MMR proteins MutSα and MutLα recruit ATR-ATRIP, TopBP1, and Chk1 to 
chromatin after base damage.  Importantly, RPA, Rad17, and Rad9 were not 
enriched on chromatin in these experiments (235-238).  This suggests that MMR  
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proteins bound to alkylated DNA may serve to scaffold ATR-ATRIP and TopBP1 
(Figure 53b). 
 Finally, there is tantalizing evidence that ATR and TopBP1 may interact 
with DNA directly.  ATR interacts with duplexed and UV-damaged DNA in 
vitro, and damaged DNA stimulates ATR activity (239, 240)  Additionally, 
TopBP1 can bind damaged DNA in vitro (240).  While no DNA binding domains 
have been described on ATR, the AlkD glycosylase binds DNA via its HEAT 
repeats (166), suggesting ATR may also bind DNA via its HEAT repeats (Figure 
53c).  Structural models of DNA-PK and ATM also support that HEAT repeats 
may contact DNA (218, 219).  How TopBP1 might interact with DNA is not clear.   
There is also 9-1-1 independent recruitment of TopBP1 to chromatin in the 
Xenopus egg extract system (114).  Additionally, a novel protein called RHINO 
interacts with Rad9 and TopBP1 through distinct domains.  Depletion of RHINO 
results in Chk1 phosphorylation defects after double strand breaks, suggesting 
that RHINO functions to promote TopBP1 recruitment (115).  Alternatively, 
RHINO binding of Rad9 and TopBP1 may regulate either or both proteins 
allosterically.   
It will be important to expand our understanding of how ATR-ATRIP and 
TopBP1 are brought together beyond the RPA-ssDNA scaffold.  Base damage 
recruitment mechanisms are of particular interest because these types of lesions 
occur often during normal cellular metabolism and because many cancer 
therapeutics are base damaging agents (241).  Understanding these other 
mechanisms of recruitment may provide novel drug targets. 
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How does TopBP1 activate ATR? 
 Mechanistic understanding of how TopBP1 activates ATR is lacking.  It is 
postulated that TopBP1 binding to ATR induces a conformational change that 
increases substrate affinity for the kinase.  This is based on the observation that 
TopBP1 greatly reduces the Km of ATR for its substrates (110).  Typically kinases 
bind substrates in their active site and at distal docking sites (242).  Binding of 
TopBP1 to ATR likely increases substrate affinity at the active site since it is a 
general activator of ATR towards all known substrates.  Only structural 
information will provide a clear picture of how TopBP1 binding increases 
substrate affinity.   
In addition to pushing towards an ATR structure, a screen for ATR 
activating mutations that bypass the requirement for TopBP1 would elucidate 
regions of the protein that may be involved in kinase activation.  Theoretical 
alignments have been done on the structure of the PI3K kinase domain and the 
related PIKKs.  While primary sequences are not similar, the predicted three-
dimensional structure of the PIKK FAT, kinase, PRD, and FATC domains is 
similar to the PI3K helical, kinase,  αK11, and αK12/αK13 domains (Figure 54a-
b) (243).  Oncogenic mutations in PI3K occur in the N-terminus of the helical 
domain.  These mutations in the helical domain disrupt interactions between the 
p110 catalytic and p85 regulatory subunits of PI3K (244).  Activating mutations 
in mTOR have been identified in yeast screens and in human tumors.  These 
TOR mutations also occur in the FAT (helical) domain as well as in the kinase 
and PRD domain (245, 246).  Similar to the PI3K mutations some of the mutations 
in the TOR FAT domain likely affect binding of regulatory proteins, such as the 
mTOR inhibitor rapamycin.  Others mutations might affect conformation.   
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Conducting a screen for activating ATR mutations would provide some 
hints into how the kinase is activated.  We have yet to identify the equivalent 
PRD mutation in yeast Mec1ATR.  However a screen for Mec1 mutations that 
suppress HU sensitivity in the ddc1Δdpb11-1 yeast strain may identify mutations 
that bypass the requirement for the two known ATR activators in yeast. Another 
possible genotype to conduct the screen with may be the use of the ddc2ATRIP-top 
mutant which disrupts Mec1ATR activation by Dpb11TopBP1.  It would be difficult to 
conduct an in vivo screen with human ATR, but an in vitro kinase activity based 
screen with randomly mutagenized ATR might yield interesting results.  
Additionally, identification of activating residues may also help develop more 
specific ATR inhibitors.  Still, only structural data can determine how these 
residues are involved in kinase activation. 
  
Regulation of TopBP1-mediated activation 
 Regulation of TopBP1 binding to ATR occurs at the level of localizing the 
two proteins in close proximity as discussed above.  However, there is evidence 
that additional mechanisms of regulation may exist.  Phosphorylation of Xenopus 
TopBP1 by xATM on S1131 potentiates xATR-ATRIP activation after DNA 
double strand breaks (118).  In addition, a phospho-mimicking mutation in the 
ATR activation domain of yeast TopBP1 also potentiates yeast ATR activation in 
vitro (112).  Both of these phosphorylation events are thought to increase TopBP1 
binding to ATR.   
 My observations that mutation of 6 candidate ATR autophosphorylation 
sites (6A-ATR) to alanine greatly increases TopBP1-mediated activation of ATR 
but not basal kinase activity in vitro also suggests that ATR dephosphorylation 
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regulates TopBP1-mediated activation.  While I do not have direct evidence that 
these residues are phosphorylated, there is data to support that phosphatase 
activity is important for ATR signaling in vivo (222).  Protein phosphatase 5 co-
immunoprecipitates with ATR, and PP5 silencing perturbs ATR-dependent Chk1 
phosphorylation after replication stress (222).  The mutated residues in 6A-ATR 
occur in two distinct clusters, the N-terminal HEAT repeat region and the FAT 
domain.  Since activating mutations in the mTOR FAT domain have been 
described (245, 246), it would not be surprising if the minimal mutations that 
cause the hyper-activation phenotype occur in the ATR FAT domain.  
Examination of the phenotype of a phospho-mimicking 6E-ATR will also be an 
important future direction.  If phosphorylation of these sites were inhibitory, 
then the 6E-ATR mutant would exhibit ATR activation defects.  6A-ATR 
expressing cells also would be insensitive to PP5-silencing.  Both ATM and 
DNA-PK interact with protein phosphatases and their signaling activities are 
regulated by phosphatases (247-249). Significantly, ATM also interacts with PP5, 
and PP5 silencing causes ATM signaling defects (250).  Study of protein 
phosphatases in ATR signaling may be an important future area of study and 
may reveal new insights into how TopBP1-mediated activation of ATR is 
regulated.     
  
Other ATR activating proteins? 
 In budding yeast, both the homologs of TopBP1Dpb11 and Rad9Ddc1 can 
activate yeast ATR (103, 112).   Whether human Rad9 can activate ATR-ATRIP 
remains to be tested.  Yeast data also suggests that these protein activators 
function in distinct phases of the cell cycle and that there may be other proteins 
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activators (251).  3A-ATR mutations described in Chapter IV separate S and G2 
functions of human ATR.  One possibility is that these residues mediate ATR 
activation mediated by Rad9 or a novel protein activator.  TopBP1 binds the ATR 
PRD to activate the kinase.  Perhaps the 3A-ATR region mediates an interaction 
with another protein activator.   
 
Phospho-regulation of DNA damage PIKKs 
The catalytic domain of most protein kinases are structurally similar, 
consisting of two lobes forming a catalytic cleft at their interface.  ATP and 
substrate binding in the catalytic cleft position ATP and the substrate in 
proximity to catalytic residues facilitating the phosphoryl transfer reaction.  In 
addition an activation loop that occurs between the two lobes but outside the 
catalytic site also is important for activity of many kinases.   
Phosphorylation regulates kinase activity by modulating access to the 
catalytic cleft and position of the catalytic residues.  For instance, 
pseudosubstrates or protein conformation may occlude substrate access to the 
catalytic cleft.  While many pseudosubstrates do not contain phospho-accepting 
residues, a few pseudosubstrates are phosphorylated to allow substrate access 
(252).  More commonly, kinase phosphorylation and dephosphorylation can 
cause a conformational change promoting substrate access and binding (253).  
Phosphorylation in the activation loop also likely mediates or stabilizes a 
catalytic cleft conformation that favorably positions catalytic residues and 
potentiates catalysis (254).  There are also a few cases where activation loop 
phosphorylation changes substrate binding (255).  Phosphorylation can serve as 
phospho-binding sites for co-factors, activators, and substrates (256, 257).  Finally 
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kinases often autophosphorylate once activated or as part of the activation 
process to mediate many of these described regulatory mechanisms (258).   
Several of these mechanisms also regulate the PIKK kinases.  ATM 
autophosphorylates on several residues, including S367, S1893, S1981, and S2996 
(162, 180, 181).  Mutation of any of these individually causes ATM signaling 
defects.  S1981 in the ATM FAT domain has been best-studied, but the function 
of S1981 remains controversial.  The Kastan group originally reported that S1981 
autophosphorylation in trans mediates an inactive dimer to active monomer 
transition.  Their data supports a model where the FAT domain interacts with 
and likely occludes the kinase domain as a dimer (Figure 55).  Upon activation, 
S1981 autophosphorylation relieves this inhibition and promotes active 
monomer formation (162).  However other groups report that ATM monomers 
can form without S1981 autophosphorylation.  Instead DNA and the MRN 
complex are sufficient to facilitate dimer to monomer transitions in vitro (171).  
 DNA-PK is phosphorylated on over 30 residues of which many are 
autophosphorylation sites, including a highly conserved T3950.  T3950 is a TQ 
and occurs in the activation loop based on comparisons to PI3K structures and 
secondary predictions of DNA-PK.  Also T3950 resides between the classical 
DFG and APE motifs, which flank activation loops (187).  ATR also contains DFG 
and APE motifs but lacks a conserved S/TQ (Figure 56).  There are several 
conserved phospho-accepting residues, though, that may be phosphorylated.  In 
future mutagenesis screens for activating mutations, this region may also be 
important to specifically target. 
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A novel regulatory region 
In addition to T3950, only two other clusters of DNA-PK 
autophosphorylation have been extensively studied.  One of these, the ABCDE 
cluster (T2609/S2612/T2638/T2647), occurs just N-terminal to the FAT domain 
and when mutated causes radiosensitivity (259).  Based on in vitro data it is 
proposed that the ABCDE autophosphorylation cluster promotes kinase 
dissociation from Ku and DNA ends (Figure 57b) (182). 
Mechanistically, DNA-PK autophosphorylation in the ABCDE cluster is 
thought to induce a conformational change in DNA-PK.  This is based on low 
resolution structures that show movement of the C-terminal FAT, kinase, PRD, 
and FATC domains upon autophosphorylation (189).  An unstructured flexible 
hinge region adjacent to the FAT domain is present in the DNA-PK crystal 
structure (Figure 57c) (218).  Since the ABCDE cluster also occurs just N-terminal 
to the FAT domain, it is possible that ABCDE autophosphorylation occurs in this 
flexible hinge region.  Indeed secondary predictions indicate that ABCDE sites 
occur in an inter-HEAT repeat loop, which is longer than a typical inter-repeat 
loop and predicted to contain little secondary structure (Figure 57a).  An 
attractive model is that ABCDE autophosphorylation in the inter-HEAT repeat 
loop mediates the conformational change in the nearby FAT, kinase, PRD, and 
FATC domains.   
Based on alignments by HEAT repeats (165), a region analogous to the 
extended inter-HEAT repeat region in DNA-PK also occurs in ATR and ATM 
(Figure 57a).  In ATM and DNA-PK these loops are targeted for functional 
autophosphorylation (181, 184).  3A-ATR residues also occur in an extended 
inter-HEAT repeat loop adjacent to the ATR FAT domain.  While 3A-ATR  
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residues may not be phosphorylated, their mutation disrupted ATR function.  
This suggests that the region is also regulatory in ATR and identifies a 
previously unknown shared regulatory region among the DNA damage PIKKs. 
 The 3A-ATR region is present in all ATR orthologues.  My preliminary 
data examining some of the conserved residues in the analogous region in 
Mec1ATR further support that this region is important for ATR function.  One 
limitation of the FRVF1349AAAA mutant was that protein stability may have 
been affected by the mutations.  In addition, there are other conserved residues 
in the region that could be examined.  It is possible that a point mutation may 
give a similar phenotype without perturbing protein folding.  If such a mutation 
were found, then a suppressor screen could provide interesting future directions 
to pursue.   
 
T1989 phosphorylation 
Three ATR phosphorylation sites appear in my mass spectrometry 
analysis and in several phospho-proteomic screens: S428, S435, and T1989.  Of 
these, I find that T1989 is DNA damage-regulated, requires ATR kinase activity 
in cells, and occurs after ATR activation.  T1989 is not essential for ATR signaling 
in cells, is not well conserved, and only causes a mild viability defect.  
Redundant phosphorylation may contribute to the lack of a phenotype.   
Drawing parallels from other well studied kinases, T1989 phosphorylation 
in the ATR FAT domain may be part of signal amplification or possibly substrate 
selectivity.  For instance, the Akt kinase contains two activating phosphorylation 
sites T308 in the activation loop and S473 on a hydrophobic motif outside the 
catalytic core.  While T308 is required for Akt activation, S473 is not required for 
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growth factor stimulated Akt activity.  However, S473 phosphorylation increases 
Akt kinase activity 10 fold (260).  T1989 phosphorylation after TopBP1-mediated 
activation of ATR may function like Akt S473 phosphorylation and serve to 
amplify kinase activity.  Defects in amplification may be more visible in normally 
proliferating cells with low levels of replication stress as compared to HU-treated 
cells.  This could explain the mild viability defect but lack of checkpoint signaling 
defect with HU treatment.  Examination of a phospho-mimicking T1989E ATR 
mutant in vivo may reveal that ATR-dependent signaling occurs with different 
kinetics.  
Akt phosphorylation of some residues but not others in the FOXO 
proteins depends on S473 (261).  This suggests that S473 phosphorylation may 
mediate substrate selectivity, or higher levels of kinase activity may be required 
to phosphorylate some substrates.  Mutation of Serine 2035 in the mTOR FRB 
domain (rapamycin binding domain) also affects substrate selectivity (262).  
Note, the FRB domain occurs between the mTOR FAT and kinase domains and 
while given a distinct name, still consists of HEAT repeats.  It is unclear if mTOR 
S2035 is phosphorylated, but this suggests that substrate selectivity in other 
PIKKs may be regulated by the FAT domain or regions nearby.  While I observe 
no Chk1 phosphorylation defects, phosphorylation of other ATR targets may be 
perturbed with T1989 mutation.  Alternatively, T1989 may not be part of the 
activation process. ATR oligomerizes, and phosphorylation in the FAT domain 
which is adjacent to the kinase domain may occur as a consequence of proximity 
and simply mark an active complex.   
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Conflicting evidence for T1989 function 
The Lee group also reports that T1989 phosphorylation is DNA damage-
regulated and is dependent on ATR kinase activity in cells.  I demonstrate that 
T1989 phosphorylation is not essential for ATR activity or ATR signaling to 
Chk1.  In contrast, the Lee study concludes that T1989 is essential for ATR 
function and Chk1 phosphorylation (263).  
Lee et al. report that ATR flox cells integrated with a T1989A mutant 
cannot form colonies after ATR deletion in a colony formation assay.  While I 
observe a mild colony forming defect, I can obtain many viable colonies from 
T1989A complemented ATR flox cells after excision of the floxed allele.  These 
colonies can be expanded into cell lines, and they only express the integrated 
mutant as determined by RT-PCR and sequencing.   
In my cellular complementation studies, I determine the expression levels 
of cell lines and importantly the percentage of cells within each line expressing 
exogenous ATR.  The Lee study did not report whether the percent expressing 
exogenous ATR in their cell line is similar.  This may be one source of 
discrepancy between our studies.  Additionally, the cell cycle distribution of their 
mutant cell line is different from the wild-type cell line even prior to adenovirus 
infection or induction of exogenous protein expression.   
Another major difference is that I do not observe defects in Chk1 
phosphorylation on S317 after HU treatment in cells only expressing a T1989A 
mutant.  However, the Lee group shows that Chk1 S345 phosphorylation after 
UV treatment requires T1989 phosphorylation.  One possibility is that there may 
be differential requirements for T1989 phosphorylation after certain types of 
damage.  Additionally as I described above, T1989 phosphorylation may dictate 
 171 
substrate selectivity towards S345 but not S317 of Chk1.  However if T1989 
phosphorylation functioned in specific contexts, it is difficult to understand how 
it could be essential for ATR function. 
Finally, Lee et al. do not provide an explanation for the essential function 
of T1989 yet the lack of conservation among ATR orthologues.  This lack of 
conservation past primate ATR is particularly striking considering the FAT 
domain and activation mechanisms are well conserved.  While the function of 
T1989 phosphorylation is unclear, data supports that it correlates with an active 
ATR kinase.  An imperative future direction will be to assess the merit of T1989 
phosphorylation as a predictive marker for response to therapies that cause DNA 
damage.    
 
Other post-translational modifications 
I have characterized T1989 and to some extent S428 and S435.  I have also 
examined 16 candidate autophosphorylation sites.  My in vivo phospho-peptide 
mapping studies illustrate that there are many more ATR phosphorylation sites 
that I have not characterized.  A major challenge going forward will be to 
identify these phospho-residues and characterize their function.  Other post-
translational modifications may regulate ATR signaling as well.  Regulatory 
acetylation catalyzed by Tip60 occurs in the ATM PRD (175, 176), but neither 
mutation of lysines in the ATR PRD nor Tip60 silencing caused ATR signaling 
defects (90).  While not a covalent modification, oxidation of conserved cysteine 
residues in the ATM FATC domain activates the ATM kinase independent of the 
MRN complex (264).  While challenging, there remains much to be learned about 
ATR post-translational modifications.   
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ATR function at replication forks 
New mechanistic insights in the ATR activation process are hampered by 
our lack of structural information. However, there has been rapid advancement 
in identifying new ATR functions using genetic ablation of ATR and mass 
spectrometry to identify ATR interacting proteins.  Despite this, how ATR 
promotes fork stability and completion of replication after replication stress is 
not well understood.   In addition when is ATR important?  During fork stalling 
or during replication after stress?  My inhibitor studies demonstrate that ATR 
activity is required during both times.  However, my inhibitor studies do not 
address what the function of ATR is during these times. 
For instance I observe that transient inhibition of ATR activity only when 
forks are stalled prevents cells from completing DNA replication after release 
from fork stalling agents.  In fact, very little DNA incorporation is able to occur 
when cells are released from this condition, as observed by essentially no 
movement of the 2N DNA content peak after release.  This suggests that there 
are very few competent replication forks.  If forks irreversibly collapse, it would 
not explain why other origins cannot rescue them once the inhibitor is removed.  
The ATR-Chk1 pathway prevents new origin firing but allows dormant origin 
firing within pre-existing replication factors during replication stress (147, 265).  
Chk1 inhibitors also increase origin firing (266).  One hypothesis is that too many 
origins have fired and have been exhausted. Future experiments examining DNA 
fibers under these conditions will give clues into the exact mechanism.  Further, 
the development of iPOND, a technique that allows analysis of replication forks 
by purifying nascent DNA, will allow us to examine factors at the stalled forks 
(229).  Recruitment of double-strand break repair proteins or other nucleases 
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would suggest that forks are collapsing or being remodeled in the absence of 
ATR.   
 
ATR signaling in the clinic 
 I began to characterize one novel ATR inhibitor.  During this time, three 
separate groups disclosed ATR inhibitors and reported the first characterization 
of these inhibitors in cells.  Like AZ20, ATM and p53-deficiency sensitized cancer 
cells to ATR inhibition, and overexpression of the oncogene cyclin E in cells 
sensitized them to DDR inhibition (205, 206, 267).  Important future directions in 
the use of ATR inhibitors in cancer therapy are to determine if certain molecular 
or genetic signatures can predict response to ATR inhibition.  My discovery of 
ATR T1989 phosphorylation may provide a useful biomarker to answer these 
questions.   
One issue with ATP analog kinase inhibitors, such as AZ20, is off-target 
inhibition of other related kinases.  Another important approach for inhibiting 
ATR signaling will be to develop peptide based inhibitors (268).  For instance, the 
RPA70N basic cleft mediates ATR-ATRIP recruitment to stalled forks as well as 
p53 and MRE11.  The PRD may also be a promising peptide based inhibitor, 
since TopBP1 binding to ATR occurs in the PRD.   
 
ATR function at the centrosome 
While centrosome biology is well outside my area of study, I end my 
dissertation with a brief discussion on intriguing connections between ATR and 
centrosomes.  Centrosomes are microtubule organizing centers whose function 
and number are crucial for chromosome segregation.  Like the genome, 
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centrosome duplication occurs in S phase and must occur only once per cell cycle 
(269).  Extra copies of centrosomes (supernumerary) has been observed in nearly 
early tumor type, and it is hypothesized that mis-segregation of chromosomes 
due to supernumerary centrosomes contributes to genomic instability (270).  In 
addition to chromosome segregation, centrosome position determines cleavage 
plane orientation during cytokinesis for asymmetric cell division in some stem 
cells (271).   
There is enticing evidence that ATR may regulate centrosomes.  First, ATR 
localizes to the centrosome (272), and ATR silencing induces centrosome re-
duplication (273).  A large-scale screen for ATM and ATR substrates identified 
many centrosome components (127, 128).  Third, a hypomorphic allele of ATR 
causes Seckel syndrome, and supernumerary centrosomes are observed in 
patient cells (274).  Furthermore Seckel syndrome is a disease characterized by 
microcephaly and growth retardation.  Autosomal recessive mutations in other 
centrosome proteins also cause microcephaly (275).  It is thought that centrosome 
dysfunction disrupts cleavage plane orientation in neural crest stem cells during 
development, resulting in defects in asymmetric stem cell division and 
microcephaly (Figure 58a) (276).  Other centrosome proteins such as Pericentrin, 
CEP152, CEP164, and CENPJ also cause Seckel syndrome (275).  These 
centrosome proteins also function in ATR signaling, and many DNA damage 
response proteins localize and signal at the centrosome (272, 277-279).   
These links between ATR and centrosome biology while tantalizing are 
preliminary.  However, the hypothesis that ATR regulates centrosome function 
may be an interesting one to test. ATR deletion in mice results in stem cell 
exhaustion (280, 281).  The widely accepted explanation is that this is due to  
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replication stress and proliferation defects in the stem cell niche.  However, 
centrosome dysfunction due to ATR deletion could also deplete stem cells by 
perturbing asymmetric division of stem cells.  If this were true, this would 
expand the field of ATR study greatly into stem cell and cancer stem cell biology.  
Supernumerary centrosomes are thought to contribute to chromosomal 
aberrations found in tumors, but perhaps mis-regulation of cleavage planes due 
to centrosome amplification contributes to the production of cancer stem cells 
and tissue disorganization (Figure 58b) (282). 
Another reason why it is attractive to hypothesize that ATR may regulate 
centrosome duplication is that, like chromosome duplication, centrosome 
duplication occurs in S phase and must occur only once (Figure 59) (269).  In 
some tumor-derived cell lines extreme lengthening of S phase with DNA 
synthesis inhibitors such as HU and aphidicolin induces centrosome re-
duplication through some unknown mechanism (269).  Since ATR is a master 
regulator of the S phase checkpoint, it may also coordinate centrosome 
duplication as part of the intra-S phase checkpoint to prevent re-duplication.   
The molecular mechanisms governing centrosome duplication are not well 
understood, making it difficult to speculate how ATR might regulate the process.   
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APPENDIX A 
 
ATR S428 AND S435 
S428 
I and others identified S428 and S435 as ATR phosphorylation sites by 
mass spectrometry (Chapter III, (125, 126)).  I examined the DNA damage-
dependency of ATR S428 phosphorylation using a commercially available 
phospho-peptide specific antibody to S428 (Cell Signaling).  Unlike T1989 
phosphorylation, S428 phosphorylation did not increase after HU treatment 
(Figure 60a), suggesting S428 phosphorylation is not DNA damage-regulated.  
Caffeine, a non-specific inhibitor of ATR and ATM, inhibited HU-induced ATR-
dependent Chk1 phosphorylation but did not reduce ATR S428 phosphorylation 
(Figure 60a).  Since S428 is not damage-regulated and does not correlate with 
ATR activity, it is not a useful marker for active ATR.   
My preliminary data indicates that ATR S428 phosphorylation is unlikely 
to be critical for the essential function of ATR to promote viability.  I integrated 
WT-ATR and S428A mutant constructs into the ATRflox/-TR cell line and 
examined colony formation following deletion of the floxed allele.  64% of WT-
ATR cells formed colonies.  Colony formation was not consistent between the 
two independent ATR-S428A cell lines.  62% of S428A2 cells formed colonies 
while only 29% of S428A1 cells formed colonies (Figure 60b).  Western blot 
analysis of ATR expression levels revealed that S428A1 expresses substantially 
lower amounts of ATR protein compared to the WT-ATR integrant.  
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However, ATR expression in the S428A2 cell line, which supported viability 
similar to WT-ATR cells, is similar to the WT-ATR cell line (Figure 60a).  Poor 
complementation of S428A1 may be a possible explanation for the low colony 
forming ability observed in S428A1 cells.  Analysis of additional S428A-ATRflox/-
TR cell lines with similar expression to WT-ATR cells will be necessary to 
definitively determine whether S428 is important for ATR function. 
 
ATR S435 
 An antibody to ATR S435 phosphorylation is not available.  However, I 
confirmed that the S435 to alanine mutation reduces phosphorylation of the 
mutant protein by metabolically labeling HU-treated cells transiently expressing 
HA-epitope tagged WT-ATR and S435A-ATR with 32P-orthophosphate and HA-
immunopurifying labeled HA-ATR.  The S435A mutant incorporated less 32P in 
vivo compared to WT-ATR (Figure 60c), supporting that the mutation perturbs 
ATR phosphorylation.  Whether DNA damage regulates this phosphorylation 
cannot be concluded from this experiment.  
I assessed whether S435 is required for the essential function of ATR to 
promote viability using the genetic complementation assay.  23% of 
uncomplemented parental ATRflox/-TR cells formed colonies after deletion of the 
floxed allele.  Integration of WT-ATR rescued viability with 64% of cells forming 
colonies.  Similarly, two independent S435A-ATRflox/- cell lines expressing at least 
the same amount of ATR protein as the WT-ATR cell line formed colonies at 62% 
and 92% (Figure 60b).  This suggests that S435 is dispensable for the essential 
function of ATR.   
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 S428 and S435 analysis suggest that the phosphorylation sites are 
dispensable for the essential function of ATR.  However, the two 
phosphorylation sites may be functionally redundant.  Analysis of a double 
S428A/S435A mutant may give different results.  S435 is one of three consecutive 
serines, and redundancy or priming may be functioning at this site.  I also only 
examined the effects of the mutations on cellular viability.  ATR has many 
functions that may not be essential or readily observed in the genetic 
complementation assay.  Examination of these mutants in different contexts and 
in different checkpoint assays may give different results.   
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